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Introduction	 Physiological	 changes	 affecting	 critically	 ill	 septic	 patients	 may	 impact	 on	 the	
effectiveness	of	licensed	methods	of	antibiotic	administration.	It	has	been	postulated	that	extending	
the	infusion	time	over	which	time-dependent	action	antibiotics	are	administered,	giving	for	example	a	
4-hour	 infusion	 rather	 than	 an	 injection	 over	 5	 minutes,	 this	 may	 increase	 efficacy	 whilst	 not	
compromising	 safety	 in	 critically	 ill	 septic	 patients.	 However,	 no	 single	 study	 or	 meta-analysis	 of	
similar	 studies	 has	 yet	 shown	 any	 significant	 benefit	 in	 patient	 orientated	 outcomes.	 Even	 so	
anecdotal	 evidence	 suggests	 that	 this	 practice	 is	 becoming	 established	 in	 the	 critical	 care	
environment	but	the	extent	of	this	in	the	United	Kingdom	(UK)	has	never	been	assessed.		Method	A	
questionnaire	was	 developed	 to	 identify	 current	 intravenous	 antibiotic	 administration	 practice	 and	
the	 factors	 influencing	 choice	 in	 UK	 critical	 care	 units	 (CCUs).	 This	 was	 circulated	 to	 critical	 care	
pharmacists	via	the	United	Kingdom	Clinical	Pharmacy	Association	message	board.	Along	side	this	a	
systematic	review	and	meta-analysis	were	conducted	to	up	date	the	evidence	base.	Results	17	of	the	
22	 antibiotics	 surveyed	 have	 a	 single	 method	 of	 administration	 used	 on	 more	 than	 50%	 of	 the	
responding	 UK	 CCUs.	 Piperacillin/tazobactam	 and	 meropenem	 are	 used	 on	 22.2%	 and	 20.3%	
respectively	 of	 responding	 CCUs	 as	 extended	 intermittent	 infusions	 (EIIs)	 and	 vancomycin	 by	
continuous	 infusion	 (CI)	 on	 49.2%.	 Respondents	 most	 commonly	 sited	 both	 favourable	
pharmacokinetic/pharmacodynamics	 and	 an	 improvement	 in	 patient	 outcomes	 as	 reasons	 for	
adopting	extended	infusions.	 In	addition,	continuous	infusions	of	vancomycin	are	seen	to	be	a	safer	
and	 a	 more	 predictable	 method	 of	 administration	 than	 intermittent	 infusions.	 Where	 extended	
infusions	were	in	use,	this	practise	was	associated	with	a	high	level	of	pharmacist	input	into	the	multi	
professional	 team	 such	 as	 seven-day	 ward	 cover.	 The	 systematic	 review	 identified	 40	 randomised	
controlled	 trials	 comparing	 extended	 infusions	 to	 the	 licensed	 administration	 practice	 of	 the	 same	
antibiotic	covering	 in	 total	16	different	antibiotics.	Statistically	significant	differences	 in	clinical	cure	
and	 microbiological/bacteriological	 cure	 were	 found	 in	 favour	 of	 extended	 infusion	 methods.	 A	
statistically	 significant	 difference	 in	mortality	was	 observed	when	 time-dependent	 antibiotics	were	
analysed	 separately.	 No	 difference	 in	 adverse	 events	 was	 identified	 between	 the	 administration	
methods.	Conclusion	 Current	UK	 critical	 care	 practice	 of	 intravenous	 antibiotic	 administration	 is	 in	
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years.	 I	 qualified	 as	 a	 pharmacist	 in	 1998	 from	 the	 University	 of	 Manchester	 and	 completed	 my	
hospital	pre-registration	training	the	following	year	at	St	Helens	and	Knowsley	Teaching	Hospitals	NHS	
Trust.	 I	 have	 since	 completed	 a	 number	 of	 postgraduate	 courses	 including	 the	 clinical	 pharmacist	
diploma	and	 supplementary	 prescribing	qualification,	 both	 at	 Liverpool	 John	Moores	University,	 an	
independent	 prescribing	 conversion	 qualification	 at	 Keele	 University	 and	 critical	 care	 course	 at	
Portsmouth	University.	 In	 2012	 I	 embarked	 part-time	 on	 a	 research	 qualification	 at	 Liverpool	 John	




with	 septic	 shock	 and	 currently	 not	 enough	 new	 antibiotics	 are	 coming	 on	 to	 the	 market	 and	
resistance	 to	 existing	 agents	 is	 increasingly	 becoming	 a	 problem.	 Approximately	 a	 decade	 ago	 I	







The	 factors	described	above	have	 in	 turn	 led	on	 to	shaping	 the	elements	of	 the	MPhil,	 I	wanted	 to	
know	what	usual	 intravenous	antibiotic	administration	practices	are	on	United	Kingdom	critical	care	





have	 collaborated	 with	 some	 of	 the	 major	 names	 working	 in	 this	 field	 both	 in	 the	 UK	 and	
internationally.	 I	 have	 co-authored	 an	 international	 survey	 of	 antibiotic	 administration	 and	
therapeutic	drug	monitoring	practice	conducted	on	behalf	of	the	European	Society	of	Intensive	Care	





Helens	 and	Knowsley	 Teaching	Hospital	NHS	Trust,	 for	 the	 “Beta-lactam	 infusion	 group	 (BLING)	 III”	
study.	This	study	will	be	by	far	the	largest	in	this	area	hoping	to	enrol	7000	critically	ill	septic	patients	
across	100	intensive	care	units	worldwide.	Based	on	all	of	this	activity	I	am	seen	within	critical	care	as	
a	 national	 expert	 on	 antibiotic	 pharmacokinetics/pharmacodynamics	 and	 stability	 and	 am	 regularly	
contacted	by	colleagues	across	the	UK	for	advice.	
The	 thesis	 that	 follows	 starts	 by	 providing	 an	 overview	 and	 background	 to	 the	 rationale	 for	 using	
extended	infusions	of	antibiotics	in	the	treatment	of	critically	ill	septic	patients.	This	is	followed	by	the	
overall	aim	and	objectives	of	this	MPhil	and	then	an	overview	of	the	methodology	used	to	answer	the	
aim.	 The	 next	 2	 chapters	 address	 in	 detail	 the	 two	 phases	 of	 the	 MPhil	 which	 were	 conducted	






Intensive	 care	medicine	 initially	 developed	 largely	 as	 a	 response	 to	 developments	 in	medicine	 and	
surgery	(Departmant	of	Health,	1999).	The	most	striking	example	of	this	was	the	response	to	the	1952	
poliomyelitis	epidemic	 in	Denmark	 (Lassen,	1953).	A	shortage	of	“iron	 lungs”	 in	hospitals	 led	to	the	
adoption	of	life	support	techniques	normally	used	only	in	operating	theatres,	with	the	most	critically	
ill	patients	being	concentrated	in	designated	areas	of	the	hospital.	These	areas	had	greater	levels	of	
nursing/medical	 intervention	 and	 observation	 than	was	 standard	 (Flaattens	 et	 al.,	 2010).	 Intensive	





Score	 (APACHE)	 (Bouch	and	Thompson,	2008),	had	been	developed	to	assess	severity	of	 illness	and	
associated	mortality.	 This	 time	 also	 saw	disciplines	 such	 as	 pharmacy	 and	physiotherapy	 becoming	
more	 directly	 involved	 in	 patient	 care	 and	 high	 dependency	 units	 (HDUs,	 areas	 of	 lower	 nurse	 to	
patient	ratios	than	ICU)	had	opened	(Reynolds	and	Tansey,	2011).	
	
In	 1999,	 the	 UK	 Department	 of	 Health	 launched	 a	 review	 of	 adult	 critical	 care	 services	 with	 the	
purpose	 of	 developing	 a	 framework	 for	 the	 future	 organisation	 and	 delivery	 of	 critical	 care	
(Departmant	 of	 Health,	 1999).	 The	 report	 suggested	 a	 patient-	 rather	 than	 specialty-oriented	 view	
and	coined	the	new	term	Comprehensive	Critical	Care.	As	a	result,	some	ICUs,	run	follow	up	clinics	to	
review	patients	post-hospital	discharge	(Griffiths	and	Jones,	2007).	Currently,	critical	care	is	a	mixture	
of	 a	 dedicated	 area	 of	 the	 hospital	 run	 by	 a	 multidisciplinary	 team	 which	 has	 all	 the	 therapeutic	
equipment	required	at	 their	disposal,	and	an	open	minded,	whole	patient	approach	to	care	before,	
during	 and	 after	 the	 patient’s	 critical	 care	 stay.	Many	 hospitals	 now	have	 critical	 care	 units	 (CCUs,	






Definition:	 The	 systemic	 response	 to	 infection	 has	 long	 been	 termed	 “sepsis”	 (Ayres,	 1985)	 but	
towards	the	end	of	the	last	century	is	was	becoming	clear	that	as	this	encompassed	the	whole	range	











new	tests	 for	biomarkers	such	as	procalcitonin	or	 interleukin	6	would	 lead	to	change	but	the	group	
expanded	 on	 the	 signs	 and	 symptoms	 and	 left	 the	 definitions	 themselves	 untouched	 (Levy	 et	 al.,	
2003).	 2016	 however	 saw	 a	 major	 change	 with	 the	 advent	 of	 the	 Third	 International	 Consensus	
Definitions	 for	 Sepsis	 and	 Septic	 Shock	 (Sepsis-3)	 (Singer	 et	 al.,	 2016).	 There	 were	 two	 main	










Prevalence:	1	 in	20	deaths	 in	England	 in	2010	was	associated	with	sepsis	 (McPherson	et	al.,	2013).	
The	 now	 defunct	 patient	 group	 term	 “severe	 sepsis”	 accounted	 for	 approximately	 25%	 of	 all	
admissions	 to	 ICU	 in	England,	Wales	and	Northern	 Ireland	between	1996	and	2004	 (Harrison	et	al.,	




In	2007	 the	Extended	Prevalence	of	 infection	 in	 Intensive	Care	 (EPIC	 II)	 study	 (Vincent	et	al.,	 2009)	
investigated	the	source	of	sepsis	on	ICU	and	identified	the	most	common	causative	microorganisms.	
This	1-day	point	prevalence	study	captured	data	on	13,796	patients	in	1,265	ICUs	across	75	countries.	
The	 lung	was	 the	most	 common	site	of	 infection	 (63.5%),	with	 the	abdomen	accounting	 for	19.6%,	
blood	15.1%	and	urinary	 tract	 at	 14.3%	 (patients	may	have	more	 than	one	 source,	hence	a	 total	 >	
100%).	46.8%	of	patients	had	Gram-positive	infections	(of	which	greater	that	2/3	were	Staphylococcus	




Treatment:	 But	 sepsis	 needn’t	mean	 death.	When	 initiated	within	 an	 hour	 of	 diagnosis,	 antibiotic	
therapy	 along	with	 appropriate	 fluid	 and	 vasopressor	 support	 has	 been	 shown	 to	 reduce	mortality	









and	 although	 some	 have	 novel	 actions	 only	 one	 of	 these,	 Linezolid	 (an	 oxazolidinone),	 has	 a	
	 23	
completely	 new	mechanism	of	 action.	 There	 has	 also	 been	 a	 steady	 decline	 over	 time	 in	 the	 total	
number	of	 individual	antibiotics	being	approved	for	human	use.	 In	the	five	year	period	1983	-	1987	
the	US	Food	and	Drug	Administration	(FDA)	approved	16	new	antibiotics	 in	comparison	to	10	in	the	
period	 1993-97	 and	 only	 2	 between	 2008-12	 (Boucher	 et	 al.,	 2013).	 In	 the	 face	 of	 a	 potential	
humanitarian	crisis	associated	with	very	common	micro-organisms	becoming	resistant	to	all	existing	
antibiotics,	 independent	 researchers	and	pharmaceutical	 companies	are	being	 incentivised	 to	 focus	
their	 effort	 on	 bringing	 new	 antibiotics	 to	 the	market	 (Hampton,	 2015).	 This	may	 slowly	 be	 taking	






The	 lack	 of	 new	 antibiotics	 coupled	 with	 ever-increasing	 resistance	 to	 existing	 agents	 (Spellberg,	
2014)	 is	making	 the	management	of	 infection	more	difficult,	which	 is	 especially	 problematic	 in	 the	
critically	 ill	 patient.	 Antibiotics	 are	 the	 only	 truly	 curative	 intervention	 that	 exists	 for	 the	 septic	




that	would	 normally	 be	 administered	 as	 a	 bolus	 injection	 or	 a	 short	 infusion	 (over	 30	minutes)	 as	
extended	 intermittent	 infusions	 (e.g.	 over	 three	 or	 four	 hours)	 or	 continuously	 (Shah	 et	 al.,	 2015).	
There	may	be	a	number	of	advantages	to	using	one	of	the	extended	administration	methods,	which	
are	 discussed	 in	 the	 next	 section,	 but	 any	 change	 in	 patient	 oriented	 outcomes	 (e.g.	 survival,	
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decreased	 hospital	 stay,	 etc.)	 have	 not	 been	 previously	 shown	 and	 this	 requires	 attention.	 The	
suitability	 of	 antibiotics	 to	 be	 given	 by	 extended	 administration	 methods	 is	 determined	 by	 their	
pharmacokinetic	and	pharmacodynamic	properties.	
	
1.3	 Factors	 affecting	 antibiotic	 therapy	 in	 critically	 ill	 patients	 –	 Pharmacokinetics	 and	
pharmacodynamics	
Pharmacokinetics	 is	 the	 effect	 the	 body	 has	 on	 a	 drug	 and	 is	 generally	 split	 into	 four	 phases:	
absorption,	distribution,	metabolism	and	elimination.	Below	is	a	brief	summary	of	each	process	and	
an	explanation	of	any	affect	environment	(critical	care)	or	disease	(e.g.	septic	shock)	has	on	it.	
Absorption:	 this	 generally	 refers	 to	 absorption	 from	 the	 gastrointestinal	 tract.	 In	 the	 critical	 care	
setting	 absorption	 often	 plays	 a	 minor	 role,	 as	 many	 antibiotics,	 are	 given	 intravenously.	 The	
assumption	being	that	the	patient	has	“absorbed”	100%	of	the	administered	dose.	
Distribution:	this	phase	describes	where	a	drug	goes	in	the	different	parts	of	the	body	and	how	long	it	
takes	 the	 drug	 to	 get	 there	 and	 equilibrate	 between	 the	 various	 tissues	 and	 organs	 of	 the	 body.	
Volume	of	distribution	(Vd)	can	be	greatly	increased	in	the	critically	ill	patient	(Gonçalves-Pereira	and	
Póvoa,	 2011)	 mainly	 due	 to	 the	 vasodilation	 associated	 with	 shock	 whereby	 fluid	 and	 protein	
(albumin)	leak	out	of	the	circulating	blood	volume	into	the	tissues	carrying	both	water	soluble	drugs	
and	 highly	 protein	 bound	 drugs	 with	 them.	 The	 increased	 volume	 of	 distribution	 in	 critically	 ill	
patients	may	impact	on	the	standard	dosing	regimens	leading	to	sub-therapeutic	blood	levels	of	drug.	
This	may	have	little	consequence	for	drugs	that	are	titrated	to	effect	(for	example,	noradrenaline	to	a	








impaired	 (for	 example,	 ischemia	 secondary	 to	 hypo-perfusion).	 If	 renal	 dysfunction	 is	 also	 present	
then	 the	potential	 for	 accumulation	of	 active	 renally	 excreted	metabolites	must	 also	be	 taken	 into	
account	when	assessing	the	dosing	of	a	hepatically	metabolised	drug.	
Elimination:	this	final	phase	general	takes	place	via	the	kidneys	(though	some	can	occur	via	the	faecal	
route).	 Critically	 ill	 patients	 often	 have	 an	 increased	 cardiac	 output	 due	 to	 fluid	 loading	 and	 the	
administration	of	drugs	 that	 increase	 the	 force	and/or	 rate	of	 cardiac	 contraction	and	 this	 leads	 to	
increased	 kidney	 perfusion,	 an	 increased	 creatinine	 clearance	 and	 a	 subsequent	 increase	 in	
drug/antibiotic	 clearance.	 This	 phenomenon,	which	 has	 been	 termed	 “augmented	 renal	 clearance”	





leaf)	 and	 therefore	 reduced	 clearance	 of	 renally	 cleared	 drugs/antibiotics	 leading	 to	 supra-
therapeutic	 levels.	 If	 the	 kidneys	 stop	 working	 altogether	 then	 their	 function	 can	 be	 replicated	
artificially	 using	 a	method	 known	 generically	 as	 renal	 replacement	 therapy.	 This	 involves	 pumping	
blood	from	the	body,	past	a	semi-permeable	membrane	and	back	into	the	body,	the	membrane	acts	
in	 a	 similar	way	 to	 the	 kidney	 and	molecules	 ordinarily	 cleared	 renally	will	 either	 travel	 across	 the	
membrane	 down	 a	 concentration	 gradient,	 referred	 to	 as	 dialysis,	 or	 down	 a	 pressure	 gradient,	
referred	to	as	filtration.	Renal	replacement	therapy	can	potentially	have	any	of	a	number	of	effects	on	
the	 pharmacokinetics	 of	 a	 drug	 including	 increasing	 the	 Vd,	 influencing	 the	 clearance	 and	 in	 some	










and	 adverse	 effects.	 Pharmacodynamic	 studies	 (known	 as	 pd-studies)	 have	 categorised	 antibiotics	
into	two	main	groups;	concentration-dependent	and	time-dependent	action	(Ambrose	et	al.,	2007).	




before	 the	micro-organism	 recovers	 and	 starts	 to	 proliferate	 again	 (Craig,	 1998).	 Large	 infrequent	
(e.g.	daily)	doses	of	these	antibiotics	provides	best	efficacy.	Aminoglycosides,	such	as	gentamicin,	fit	
into	 this	 group.	 Time-dependent	 action	 antibiotics,	 the	 second	 group,	 have	 been	 shown	 to	 have	
greatest	efficacy	when	the	serum	antibiotic	concentration	is	maintained	above	the	MIC	for	prolonged	
periods	of	the	dosing	interval	(described	as	time	greater	than	the	MIC	or	T>MIC).	It	follows	therefore	
that	 a	 method	 of	 delivery	 that	 maintains	 the	 concentration	 consistently	 above	 the	 MIC	 (more	










or	 T>MIC.	A	 final	 parameter	 exists,	 the	 ratio	 of	 the	 area	under	 the	 concentration	 time-curve	 at	 24	
hours	 (AUC)	 to	 the	 MIC	 (abbreviated	 to	 AUC0-24:MIC	 or	 AUC/MIC),	 where	 neither	 the	 peak	
concentration	nor	 the	time	spent	above	the	MIC	alone	matter	but	 the	 total	concentration	over	 the	
MIC	 over	 24	 hours	 predicts	 efficacy	 (Moise	 et	 al.,	 2000;	 Abdul-Aziz	 et	 al.,	 2015).	 Somewhat	
confusingly	 antibiotics	 described	 as	 both	 time-dependent,	 such	 as	 vancomycin	 and	 linezolid,	 and	















relatively	 recently	 (Roberts	 et	 al.,	 2009c).	 Using	 this	 approach	 is	 rational	 for	 antibiotics	with	 time-
dependent	action,	in	particular	for	those	antibiotics	in	which	T>MIC	is	the	parameter	best	correlating	
with	 efficacy	 (Shah	 et	 al.,	 2015).	 Researchers	 have	 taken	 two	 methodological	 approaches	 to	
investigating	the	effects	of	extended	administration	method,	either	focusing	on	the	pk/pd	interaction	
between	 the	 antibiotics	 and	 the	 human	 subjects	 (both	 healthy	 and	 infected)	 or	 by	 investigating	
efficacy	and	safety	in	clinical	practice.	




injection	 or	 short	 infusions,	 but	worth	 considering	 nonetheless	 as	 it	 would	 potentially	 achieve	 the	
desired	outcome	of	maintaining	the	antibiotic	level	in	the	serum	above	the	MIC	for	prolonged	periods	




be	effective.	This	might	not	 just	 lead	 to	 treatment	 failure	but	also	promote	antibiotic	 resistance	by	
maintaining	 levels	 in	 the	 “mutant	 selection	window”,	 an	 antibiotic	 concentration	 at	 the	 target	 site	
that	is	above	the	MIC	so	will	kill	sensitive	organisms	but	at	a	concentration	that	is	too	low	to	kill	the	
less	 susceptible	organisms	effectively	promoting	 their	 growth	 (Abdul-Aziz	 et	 al.,	 2015).	 Even	with	a	
loading	 dose	 there	 are	major	 drawbacks	 predominately	 relating	 to	 cost	 effectiveness,	 for	 example	





1.4.2	 Continuous	 infusions:	 Antibiotics	 may	 be	 administered	 as	 a	 continuous	 infusion	 over	 the	
duration	 of	 treatment.	 The	 administration	 of	 vancomycin	 by	 this	 method	 is	 both	 logical	 and	 well	
described	 (James	 et	 al.,	 1996;	Wysocki	 et	 al.,	 2001)	 as	 is	 the	 pharmacokinetics	 in	 different	 patient	
groups	 (Rybak	 et	 al.,	 1990;	 Grace,	 2012)	 but	 there	 are	 no	 prospective	 studies	 showing	 patient-
orientated	 benefits	 (Roberts	 et	 al.,	 2008b;	 Gonçalves-Pereira	 and	 Póvoa,	 2011)	 and	 the	 use	 of	





















practices	 in	 UK	 CCUs	 have	 never	 been	 investigated.	 It	 is	 important	 to	 understand	 the	 current	 UK	









i. To	ascertain	current	usual	 local	methods	of	 intravenous	antibiotic	administration	across	UK	
critical	care	units	to	define	if	a	common	practice	exists	
ii. To	 ascertain	 the	 factors	 influencing	 the	 adoption	 of	 extended	 or	 continuous	 infusions	 of	
antibiotics.	
























does	 the	published	 literature	support	 the	use	of	extended	 infusions	of	antibiotics	 in	 the	critically	 ill	
patient	 population?	 This	 thesis	 will	 bring	 these	 elements	 together	 and	 reflect	 in	 the	 discussion	
whether	UK	CCU	practice	is	supported	by	the	published,	peer-reviewed	evidence	base.	
2.1.1	 Phase	1:	Assessing	intravenous	antibiotic	administration	practice		
There	are	numerous	approaches	 that	could	be	 taken	 to	collecting	data	on	current	practice	but	 two	
key	elements	of	 the	study	needed	 to	be	 taken	 into	consideration	when	making	 this	choice,	namely	
the	 geographical	 population	 to	be	 sampled	 and	who	 is	 going	 to	be	providing	 the	data.	Once	 these	






the	evidence	base	and	 so	 a	potential	 approach	would	be	 to	 investigate	practice	on	a	wider,	 global	
level.	An	 international	or	Europe-wide	study	of	practice	would	have	had	wide	 reaching	 interest	but	
would	not	have	provided	any	meaningful	results	beyond	simply	stating	what	practices	exist.	Globally	

















The	 common	 microorganisms,	 resistance	 patterns	 and	 antibiotic	 availability	 are	 also	 relatively	
uniform	across	the	UK.	The	number	of	critical	care	units	across	the	UK	is	known	and	so	an	accurate	
response	rate	could	be	calculated	and	although	response	was	likely	to	be	lower	and	the	practicalities	




Critical	 care	 pharmacists	 were	 chosen	 as	 the	 target	 recipients	 of	 the	 questionnaire	 based	 on	 a	
number	of	factors.	Specialist	pharmacists	in	general	have	day-to-day	involvement	in	patient	care	and	
as	 part	 of	 their	 role	 will	 be	 involved	 in	 the	 development	 and	 implementation	 of	 local	 guidance	
pertaining	to	drug	administration.	A	fundamental	part	of	the	pharmacists	role	is	to	check	the	accuracy	
of	 prescriptions	 in	 line	with	 licensed	 or	 local	 practice	 and	 advise	 staff	 of	 all	 grades	 and	 disciplines	
involved	in	direct	patient	care	on	how	to	prescribe,	prepare	and	administer	medicines	safely.	Because	
of	 these	 factors	 pharmacists	 will	 be	 aware	 of	 what	 actually	 happens	 as	 usual	 practice	 in	 their	
specialist	area,	in	this	instance	critical	care	and	are	therefore	the	ideal	respondents.	A	final	aspect	is	
the	fact	that	the	United	Kingdom	Clinical	Pharmacy	Association	(UKCPA)	critical	care	message	board	
provides	 a	 simple	 way	 of	 contacting	 the	 target	 population;	 not	 all	 critical	 care	 pharmacists	 are	







process	 under	 investigation,	 in	 this	 instance	 intravenous	 antibiotic	 administration.	 This	 interaction	
can	 range	 from	 face-to-face	 meetings	 with	 small	 groups	 of	 participants	 through	 to	 sending	
questionnaires	 out	 to	 very	 large	 numbers	 of	 participants	 and	 hoping	 the	 majority	 of	 them	 will	
respond.		
Focus	groups	are	the	most	personal	option	and	involve	gathering	small	groups	of	participants	with	a	
moderator	 guiding	 the	 discussion.	 These	 groups	 lend	 themselves	 to	 open	 discussion	 where	 the	
investigator	 may	 not	 need	 or	 want	 clear-cut	 binary	 yes/no	 answers	 and	 exploring	 and	 clarifying	
perspectives	is	actively	encouraged	(Tong	et	al.,	2007).	They	are	however	a	very	time	consuming	and,	






in	 epidemiological	 studies	 as	 a	 practical	 and	 structured	method	 of	 data	 collection	 (Edwards	 et	 al.,	
2010).	A	questionnaire	consists	of	a	 list	of	questions	 in	either	an	“open”	 (free	text)	or	“closed”	 (set	
options)	style	and	are	designed	to	answer	the	over	all	question	being	posed.	The	investigator	tailors	
the	questionnaire	 to	suit	his	or	her	own	needs;	using	predominantly	closed	type	questions	restricts	
the	 respondents	 options	 and	 ability	 to	 express	 themselves	 but	 therefore	 reduces	 variability	 of	
response	making	 the	 results	much	more	amenable	 to	 statistical	 analysis	 (Boynton	and	Greenhalgh,	
2004).		






that	 participants	 choice	 of	 practice.	 This	 method	 also	 has	 major	 drawbacks	 which	 include	 the	
potential	for	the	researcher	to	create	bias	in	the	responses	and	the	fact	that	this	approach	could	be	
prohibitively	 time	 consuming,	 expensive	 and	 simply	 not	 practical	 for	 a	 survey	 of	 practice	 covering	







sole	 target	 participants	 for	 this	 study	 but	 as	 a	 list	 of	 critical	 care	 pharmacists	 for	 UK	 CCUs	 is	 not	
available	the	only	means	of	contacting	potential	participants	was	either	a	generic	letter	sent	to	“the	
pharmacist”	on	each	UK	CCU	or	to	post	the	link	to	the	questionnaire	on	the	United	Kingdom	Clinical	
Pharmacy	Association	Critical	Care	Group	message	board,	 the	 later	option	was	 chosen	 for	practical	
reasons.		
A	systematic	review	and	meta-analysis	performed	for	the	Cochrane	collaboration	 in	2009	examined	
factors	 influencing	 the	 response	 rate	 to	 both	 postal	 and	 electronic	 questionnaires	 (Edwards	 et	 al.,	
2010).	 Of	 the	 513	 eligible	 trials	 examined	 32	 investigated	 electronic	 questionnaires	 reporting	 27	
different	 interventions.	 The	 positive	 outcomes	 associated	 with	 statements	 about	 response	 rate	 to	
date,	use	of	a	white	background	and	offering	to	report	results	back	to	respondents	were	all	taken	into	
account	 in	 the	 design	 of	 this	 questionnaire	 and	 supporting	 information	 sent	 to	 the	 potential	
participants.		
2.1.1.4	Choice	of	statistical	methods	
Where	possible	 the	questionnaire	used	closed	questions	 restricting	 the	 respondent	 to	a	number	of	
options	and	no	free	text.	In	the	first	instance	all	data,	demographic	and	outcome,	was	analysed	using	
























can	 potentially	 range	 from	 expert	 opinion	 or	 best	 practice	 through	 to	 one	 or	 more	 large	 well-
conducted	 randomised	 controlled	 trials	 (RCTs).	 Many	 common	 conditions	 such	 as	 myocardial	
infarction	or	diabetes	management	will	 have	 large	 influential	 RCTs	 that	will	 guide	 therapy	and	one	




with	sepsis	 is	 likely	 to	have	a	very	variable	cohort	of	patients	with	different	 infection	sites/sources,	
causative	organisms,	pre-existing	co-morbidities	(e.g.	chronic	obstructive	pulmonary	disease,	diabetes	
mellitus,	 etc.)	 and	 new	 clinical	 conditions	 (acute	 kidney	 injury,	 atrial	 fibrillation,	 etc.).	 All	 of	 these	
confounders	potentially	hide	any	important	results.	Considering	these	factors,	studies	in	the	critically	
ill	 patient	 tend	 to	 target	 the	 enrolment	 of	 relatively	 small	 numbers	 and	 so	 the	 choice	 of	 primary	
outcomes	tends	to	reflect	this	with	studies	frequently	now	focusing	on	length	of	stay	on	critical	care	
and	morbidity	 rather	 than	mortality.	 	 Even	 the	biggest	 critical	 care	 studies	 rarely	 show	outstanding	
differences	between	therapies.	Searching	for	and	finding	all	publications	addressing	a	specific	clinical	
question	 then	analysing	 the	pooled	 results	 can	potentially	 identify	benefits	of	 therapies	 that	would	
otherwise	be	missed;	 the	 first	part	of	 this	process	 is	known	as	a	systematic	 review	of	 the	 literature	
and	the	second	part	is	a	meta-analysis.	
The	 key	 to	 both	 processes	 is	 rigor	 and	 therefore	 thoroughness	 and	 openness	make	 this	means	 of	
generating	evidence	very	powerful.	For	example,	one	main	element	of	the	systematic	review	process	










expanded	 to	 include	 the	 systematic	 review	process	 –	 the	Preferred	Reporting	 Items	 for	 Systematic	
Reviews	 and	 Meta-Analysis	 (PRISMA)	 statement	 (Moher	 et	 al.,	 2009)	 and	 finally	 the	 PRISMA-P	
statement	focussing	specifically	on	the	initial	protocol	writing	(Moher	et	al.,	2015).	The	later	of	thse	
strongly	 recommends	 that	 the	preparation	and	 registration	of	 systematic	 review	and	meta-analysis	
protocols	occur	to	reduce	publication	bias	of	systematic	reviews	and	to	reduce	the	risk	of	duplication	
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of	 effort.	 An	 example	 of	 such	 a	 register	 is	 the	 International	 Prospective	 Register	 of	 On-going	
Systematic	Reviews	called	PROSPERO	http://www.crd.york.ac.uk/prospero		









conducted	 properly	 it	 provides	 the	 highest	 grade	 of	 evidence	 and	 thus	 is	 the	 logical	 choice	 for	
addressing	this	phase	of	work.	
A	protocol	was	developed	in	line	with	the	PRISMA-P	statement	(Moher	et	al.,	2015)	and	based	around	
the	 PICOS	 (population,	 intervention,	 control,	 outcomes,	 study	 design)	 method	 of	 formulating	 a	
question.	This	protocol	was	registered	on	the	PROSPERO	database	(PROSPERO	ID	CRD42017067213)	
at	 the	 outset	 of	 the	 study.	 The	 systematic	 review	 included	 only	 randomised	 controlled	 trials	 (RCT)	
(blinded	or	open	label)	comparing	two	different	administration	method	of	the	same	antibiotic	in	adult	





The	 major	 limitation	 of	 the	 process	 of	 systematic	 review	 is	 that	 one	 could	 argue	 that	 the	 overall	





The	 Preferred	 Reporting	 Items	 for	 Systematic	 Reviews	 and	Meta-Analyses:	 The	 PRISMA	 Statement	
(Moher	 et	 al.,	 2009)	 clearly	 sets	 out	 high	 level	 details	 of	 what	 the	 international	 group	 of	 expert	
authors	 consider	 to	be	 the	minimum	standards	 for	all	 aspects	of	 the	 statistical	 analysis	of	 the	data	




1. Risk	 of	 bias	 in	 individual	 studies	 –	 “Describe	 methods	 used	 for	 assessing	 risk	 of	 bias	 of	
individual	studies	(including	specification	of	whether	this	was	done	at	the	study	or	outcome	
level),	and	how	this	information	is	to	be	used	in	any	data	synthesis”	(Moher	et	al.,	2009).	The	
Cochrane	 risk	of	bias	 tool	 (Higgins	et	al.,	2011)	was	adopted	 for	 this	 study,	 it	 consists	of	5	
items	 for	 which	 there	 is	 evidence	 for	 their	 biasing	 influence	 on	 the	 estimates	 of	 an	
intervention’s	effectiveness	in	RCTs	(sequence	generation,	allocation	concealment,	blinding,	




or	 unclear)	 within	 each	 item	 and	 presented	 pictographically	 in	 table	 4.1	 “Methodological	
quality	summary”	in	the	results	section	of	chapter	4.	
2. Summary	measures	–	“State	 the	principal	 summary	measures	 (e.g.,	 risk	 ratio,	difference	 in	
means)”	 (Moher	 et	 al.,	 2009).	 All	 outcomes	 in	 this	 study	 were	 dichotomous	 and	 the	
treatment	effect	was	measured	using	the	risk	ratio	(RR)	with	its	associated	95%	confidence	
interval	 (95%	CI)	 and	using	a	 random-effects	model.	A	 random-effects	model	was	deemed	
most	appropriate	due	to	the	 large	amount	of	perceived	clinical	heterogeneity	between	the	
studies	and	to	balance	the	weighting	applied	to	the	studies	so	as	not	to	reduce	the	effect	of	
the	 many	 smaller	 studies.	 The	 Cochrane	 handbook	 (http://handbook-5-1.cochrane.org;	
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section	9.2.2.1)	suggests	that	interpretation	of	odds	is	more	complicated	than	risk	hence	the	
choice	of	RR	in	this	meta-analysis.		3. Synthesis	 of	 results	 –	 “Describe	 the	 methods	 of	 handling	 data	 and	 combining	 results	 of	
studies,	 if	done,	 including	measures	of	consistency	(e.g.,	 I2)	for	each	meta-analysis”	(Moher	
et	al.,	2009).	The	I2	statistic	has	been	used	as	the	main	measure	of	statistical	heterogeneity.	
Overall	heterogeneity	should	be	assessed	in	the	wider	context	of	the	studies	included	but	as	
a	general	rule	 I2	greater	than	50%	was	considered	as	 important	heterogeneity,	an	 I2	of	 less	
than	30%	was	considered	lower	risk	(Higgins	and	Thompson,	2002;	Higgins	et	al.,	2003).	
4. Risk	 of	 bias	 across	 studies	 –	 “Specify	 any	 assessment	 of	 risk	 of	 bias	 that	 may	 affect	 the	
cumulative	evidence	(e.g.,	publication	bias,….)”	(Moher	et	al.,	2009).	Evidence	of	publication	
bias	was	assessed	both	visually	using	funnel	plots	(Egger	et	al.,	1997)	and	statistically.	Duval	
and	 Tweedie’s	 Trim	 and	 Fill	 (Duval	 and	 Tweedie,	 2000)	 method	 was	 used	 to	 impute	 the	





analyses,	 meta-regression),	 if	 done,	 indicating	 which	 were	 pre-specified”	 (Moher	 et	 al.,	
2009).	The	only	subgroup	defined	for	separate	analysis	a	priori	was	individual	antibiotics	that	
featured	in	5	or	more	articles.	In	view	of	the	results	of	the	questionnaire	reported	in	chapter	
3,	 antibiotics	 with	 significant	 UK-wide	 usage	 as	 extended	 infusions	 were	 also	 analysed	
individually.	 Subgroups	were	 analysed	 using	 the	 same	 statistical	methods	 as	 described	 for	
the	 main	 results.	 Specifics	 of	 the	 sensitivity	 analysis	 were	 not	 defined	 a	 priori	 but	 were	
performed	on	primary	outcomes	and	any	outcomes	 yielding	a	 significant	 result.	 Sensitivity	
analysis	was	 conducted	 to	assess	 the	 impact	of	decisions	made	 in	 the	design	phase	of	 the	





To	 summarise,	 the	 final	 approach	 taken	 to	 address	 the	 aim	 of	 the	 study	 was	 as	 follows.	 A	
questionnaire	 was	 circulated	 to	 UK	 critical	 care	 pharmacists	 electronically	 via	 the	 UKCPA	 CCG	
message	 board	 to	 assess	 current	methods	 of	 intravenous	 antibiotic	 administration	 practice	 on	 UK	
critical	care	units.	Along	side	this,	a	systematic	review	and	meta-analysis	of	published	RCTs	comparing	





















Choice	of	 antibiotic	 in	 the	hospital	 setting	 is	 largely	 guided	by	 local	policy	 and	antibiotic	 guidelines	
that	 have	 been	 developed	 with	 common	 organisms/infection	 sites	 and	 resistance/susceptibility	




At	 the	 time	 of	 conception	 of	 this	 study	 there	was	 nothing	 in	 the	 published	 literature	 investigating	
current	 practice.	 Conducted	 at	 a	 similar	 time	 to	 this	 questionnaire	 and	 published	 in	 2015	 was	 an	
international	survey	led	by	Alexis	Tabah	(Tabah	et	al.,	2015),	it	investigated	what	current	practices	of	
antimicrobial	dosing	and	monitoring	exist	in	Intensive	Care	Units	(ICU)	around	the	world.	402	health	
care	 professionals	 from	 53	 countries	 responded.	 Respondents	 were	 predominantly	 specialist	 ICU	
medical	staff	(78%)	with	12%	being	pharmacists.	The	survey	was	based	around	a	clinical	scenario	with	
a	questionnaire	devised	to	gather	information	on	the	dosing,	administration	and	monitoring	practices	
for	5	antibacterial	agents/groups	commonly	used	 in	critically	 ill	patients,	namely	glycopeptides	 (e.g.	
vancomycin),	piperacillin/tazobactam,	carbopenems,	aminoglycosides	and	colistin.	The	study	showed	



























A	survey	of	UK	practice	would	provide	 insight	 into	current	approaches	and	any	deviations	 from	the	
methods	of	administration	detailed	in	the	marketing	authorisation.	It	would	also	allow	us	to	examine	
































launch	 (1950,	 1980	 and	 1982	 respectively)	 to	 31st	 May	 2013.	 Searches	 were	 restricted	 to	 human	
studies	 but	 performed	without	 any	 other	 limits	 such	 as	 language	 or	 age	 of	 subject.	 Searches	 used	
combinations	of	the	following	terms	matched	in	each	database	thesaurus:	critical	care,	intensive	care,	
antibiotic,	 anti-bacterial	 and	health	 care	 survey	 (see	 appendix	 6	 for	 full	 search	 strategy).	 Titles	 and	
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abstracts	were	 retrieved	 and	 reviewed.	 Duplicates	were	 removed	 and	 articles	were	 filtered	 at	 this	
stage	to	exclude	those	without	an	English	abstract,	whose	subject	was	the	paediatric	population,	and	

































Choice	 of	 the	 topics	 and	 questions	 for	 inclusion/exclusion	 in	 the	 questionnaire	 was	 guided	 by	
personal	experience	of	the	subject	matter	and	by	taking	into	account	published	literature	to	identify	
common	 themes	 and	 relevant	 antibiotics	 (Craig,	 1998;	 Roberts	 et	 al.,	 2011a;	 Drusano	 and	 Lodise,	
2012;	Carlier	et	al.,	2013;	Dulhunty	et	al.,	2013a).		
	










to	 set	 answers.	 The	 perceived	 benefit	 of	 this	 style	 of	 question	 was	 that	 it	 would	 categorise	 the	
information	received.	Where	this	approach	wasn’t	possible	a	semi-closed	style	was	used	with	drop-
down	options	with	an	option	for	free-type	responses.	Open	questions	were	limited	to	instances	were	




















Short	infusion/Bolus	(S/B)	 Short	 infusion	 as	 per	 the	 Summary	 of	 Product	
Characteristics	 (SPC)	 or	 Bolus	 injection	
dependent	on	dose.	For	some	antibiotics	the	SPC	
suggests	 different	 methods	 of	 administration	












Ethical	approval	 for	 the	study	was	obtained	 from	Liverpool	 John	Moores	University	Research	Ethics	
Committee	(UREC)	(13/SPS/044).		
	
Three	 questions	 were	 included	 that	 could	 potentially	 allow	 identification	 of	 the	 pharmacist	 who	
completed	the	questionnaire;	NHS	Trust,	grade	and	level	of	experience.	These	details	were	required	
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Following	 UREC	 approval,	 the	 questionnaire	 underwent	 a	 pilot	 phase	 on	 four	 purposively	 sampled	
critical	care	pharmacists	in	other	UK	NHS	Trusts	to	assess	validity	and	reliability	and	to	test	practical	
issues	such	as	ease	of	use,	unforeseen	question	ambiguity,	etc.	The	questionnaire	was	then	further	







after	 the	 initial	 posting	 (see	 appendix	 3	 for	 the	 participant	 information	 sheet	 and	 appendix	 4	 for	
copies	 of	 the	messages	 posted).	 There	 are	 approximately	 240	 CCUs	 in	 the	 UK	 and,	 at	 the	 time	 of	
posting	 the	 link,	 600	 pharmacists	 registered	 with	 the	 CCG	 message	 board.	 As	 there	 were	 more	
pharmacists	registered	with	the	message	board	than	there	are	CCUs	in	the	UK	(and	it	is	the	practice	
on	the	CCUs	that	the	research	is	focused	on)	there	was	a	risk	of	duplicate	responses	(from	the	same	
hospital	by	different	pharmacists).	The	approach	to	duplicates	was	standardised	 for	 the	study;	 they	
were	 screened	 by	 CCU	 and	 the	 response	 from	 the	 most	 experienced	 pharmacist	 selected.	 This	
method	 was	 selected	 on	 the	 basis	 that	 they	 would	 potentially	 be	more	 knowledgeable	 about	 the	
practices	than	more	junior	pharmacists.	Agenda	for	Change	band	(AfC)	(Jones	et	al.,	2005)	was	used	
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as	 the	marker	of	 experience	 (8b-9	being	 the	most	experienced	and	6	being	 the	 least),	 if	 there	was	
more	than	one	pharmacist	on	the	same	band	the	years	experience	was	taken	into	account	next.	A	list	
of	 all	 Critical	 Care	 Units	 was	 obtained	 from	 the	 Intensive	 Care	 National	 Audit	 &	 Research	 Centre	
(ICNARC,	England,	Wales	and	Northern	Ireland)	and	the	Scottish	Intensive	Care	Societies	Audit	Group	






Before	the	questionnaire	was	 launched,	a	plan	of	statistical	analysis	was	developed	and	 included	 in	




stated	 factors	 influencing	 practice	 and	 the	 rate	 of	 TDM	 (questions	 12-17).	 Usual	 practice	 was	
identified	as	existing	when	an	antibiotic	was	administered	by	the	same	method	on	greater	than	50%	








A	 structured	 search	 of	 the	 literature	 found	 no	 articles	 reporting	 surveys	 of	 antibacterial	























90.6%	 (58/64)	 of	 responding	 CCUs	 were	 from	 England,	 one	 CCU	 was	 in	 Northern	 Ireland	 and	 the	
remaining	 5	 in	 Scotland	 (Table	 3.2).	 At	 least	 one	 unit	 responded	 from	 the	majority	 of	 Critical	 Care	
Networks	(CCNs)/regions	in	the	UK	as	defined	by	ICNARC/SICSAG	(23/29,	Chart	3.1).	The	specialty	of	






the	 consultant-led	 ward	 round	 (Table	 3.3).	 81.3%	 (52/64)	 of	 units	 had	 a	 ward	 round	 with	 the	
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The	 usual	method	 of	 administration	 of	 22	 antibacterials	was	 ascertained	 on	 each	 CCU	 (Table	 3.4).	
Frequency	analysis	shows	that	17	of	the	22	antibiotics	have	a	single	method	of	administration	used	on	
more	than	50%	of	the	responding	CCUs	(Table	3.5).		
Four	 antibiotics	 are	 administered	 on	 at	 least	 20%	 of	 CCUs	 by	 EII	 or	 CI:	 Piperacillin/tazobactam,	
doripenem,	meropenem	and	 vancomycin.	Doripenem	 is	 only	 used	 on	 3	 of	 the	 responding	 CCUs	 so	
was	not	included	in	further	analysis.	Piperacillin/tazobactam	and	meropenem	are	used	on	22.2%	and	
20.3%	respectively	of	responding	CCUs	as	EIIs	and	vancomycin	by	CI	on	49.2%	(Table	3.4).	Different	
factors	 significantly	 affected	 the	 adoption	 of	 EII/CI	 for	 each	 drug.	 Higher	 pharmacist	 AfC	 banding	
(p=0.028),	 greater	 pharmacist	 cover	 (p<0.001)	 but	 not	 pharmacist	 attendance	 on	 the	 ward	 round	
(p=0.82)	and	greater	microbiologist	input	(p=0.031)	all	significantly	influenced	the	adoption	of	EIIs	as	
the	usual	method	of	administration	of	piperacillin/tazobactam	in	preference	to	the	method	stated	in	
the	 SPC.	 Practice	 also	 varied	 significantly	 between	 CCNs/Regions	 (Table	 3.6)	 with	 some	 regions	
adopting	 predominantly	 EII	 usage	 and	 others	 using	 either	 bolus	 or	 short	 infusion.	 The	 only	 factor	
significantly	 driving	 EII	 administration	 of	 meropenem	 was	 greater	 pharmacist	 cover	 (p<0.001,	 see	
Table	3.7).	Adoption	of	a	policy	of	vancomycin	administration	by	CI	was	significantly	affected	by	the	
presence	of	the	pharmacist	on	the	consultant-led	ward	round	(p=0.03,	see	Table	3.8).	7.8%	(5/64)	of	
CCUs	 altered	 the	 method	 of	 administration	 in	 patients	 on	 renal	 replacement	 therapy	 (Table	 3.9).	
15.6%	 (10/64)	of	CCUs	altered	 the	method	of	 administration	 for	other	patient	 factors	 (Table	3.10).	
The	 most	 commonly	 stated	 rationale	 for	 using	 EII/CI	 was	 “Evidence	 Based	 –	
pharmacokinetic/pharmacodynamics	 properties”	 with	 48.4%	 (31/64)	 of	 CCUs,	 cost	 was	 the	 least	
popular	 with	 only	 3.7%	 (2/64)	 (Table	 3.11).	 9.4%	 (6/64)	 thought	 that	 the	 total	 daily	 dose	 of	 drug	
differed	when	using	EII/CI,	in	all	cases	the	drug	in	question	was	vancomycin,	on	2	CCUs	they	thought	
they	would	use	a	 lower	over	all	dose	but	on	4	 they	thought	 they	would	use	a	bigger	dose.	No	CCU	
used	EII	with	the	specific	aim	of	reducing	the	total	daily	dose	of	antibacterial	required.	 	Therapeutic	
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Country	 	 	 	
	 England	 58	 (90.6)	
	 Wales	 0	 (0)	
	 Scotland	 5	 (7.8)	







	 	 	 	
Type	of	CCU	 	 	 	
	 Medical	 0	 (0)	
	 Surgical	 1	 (1.6)	
	 General/mixed	 60	 (93.7)	
	 Cardiothoracic	 1	 (1.6)	
	 Neurosciences	 0	 (0)	
	 Other*	 2	 (3.1)	
	 Not	known	 	 	
Size	of	CCU	 	 	 	
	 <10	beds	 14	 (21.9)	
	 10-20	beds	 31	 (48.4)	
	 >20	beds	 12	 (18.8)	





























Agenda	for	Change	band	 	 	 	
	 6	 0	 (0)	
	 7	 6	 (9.4)	
	 8a	 31	 (48.4)	
	 8b-9	 27	 (42.2)	
Number	of	years	working	in	critical	care	 	 	 	
	 <1	 2	 (3.1)	
	 1-5	 11	 (17.2)	
	 6-10	 19	 (29.7)	
	 >10	 32	 (50.0)	
Does	the	CCU	have	pharmacist	cover	 	 	 	
	 Never	 0	 (0)	
	 Rarely/ad	hoc	 1	 (1.6)	
	 Weekdays	 52	 (81.3)	
	 Weekdays	and	Saturdays	 0	 (0)	




















































B	 S/B	 S/SPC	 EII	 CI	 N/A	 Number	
of	CCUs	
Benzylpenicillin	 30		 (48.4)	 6	 (9.7)	 22	 (35.5)	 	 	 4		 (6.4)	 2	 62	
Flucloxacillin	 30	 (46.9)	 8	 (12.5)	 22	 (34.4)	 	 	 4	 (6.2)	 	 64	
Amoxicillin	 38	 (65.5)	 8	 (13.8)	 12	 (20.7)	 	 	 	 	 6	 58	
Ampicillin	 1	 (50)	 	 	 1	 (50)	 	 	 	 	 62	 2	
Co-amoxiclav	 40	 (67.8)	 	 	 13	 (22)	 6	 (10.2)	 	 	 5	 59	
Piperacillin/	
Tazobactam	
17	 (27)	 	 	 32	 (50.8)	 14	 (22.2)	 	 	 1	 63	
Ticarcillin/	
Clavulanic	acid	
	 	 	 	 10	 (100)	 	 	 	 	 54	 10	
Cefotaxime	 20	 (60.6)	 2	 (6.1)	 11	 (33.3)	 	 	 	 	 31	 33	
Ceftazidime	 20	 (40.8)	 1	 (2)	 20	 (40.8)	 8	 (16.4)	 	 	 15	 49	
Ceftriaxone	 22	 (36.7)	 1	 (1.7)	 33	 (55)	 4	 (6.6)	 	 	 4	 60	
Cefuroxime	 24	 (61.5)	 	 	 11	 (28.2)	 4		 (10.3)	 	 	 25	 39	
Doripenem	 	 	 	 	 2	 (66.7)	 1	 (33.3)	 	 	 61	 3	
Ertapenem	 5	 (13.2)	 	 	 33	 (86.8)	 	 	 	 	 26	 38	
Imipenem/	
Cilastatin	
	 	 	 	 5	 (100)	 	 	 	 	 59	 5	
Meropenem	 29	 (45.3)	 4	 (6.3)	 18	 (28.1)	 13	 (20.3)	 	 	 	 64	
Tigecycline	 	 	 	 	 38	 (100)	 	 	 	 	 26	 38	
Clarithromycin	 	 	 	 	 63	 (98.4)	 1	 (1.6)	 	 	 	 64	
Clindamycin	 	 	 	 	 62	 (96.8)	 2	 (3.2)	 	 	 	 64	
Vancomycin	 	 	 	 	 32	 (50.8)	 	 	 31	 (49.2)	 1	 63	
Teicoplanin	 34	 (57.6)	 	 	 25	 (42.4)	 	 	 	 	 5	 59	
Linezolid	 	 	 	 	 60	 (96.7)	 2	 (1.7)	 	 	 2	 62	




































Amoxicillin	 B	 38/58	 (65.5)	
Co-amoxiclav	 B	 40/59	 (67.8)	
Piperacillin/Tazobactam	 S/SPC	 32/63	 (50.8)	
Ticarcillin/Clavulanic	acid	 S/SPC	 10/10	 (100)	
Cefotaxime	 B	 20/33	 (60.6)	
Ceftriaxone	 S/SPC	 33/60	 (55)	
Cefuroxime	 B	 24/39	 (61.5)	
Doripenem	 S/SPC	 2/3	 (66.7)	
Ertapenem	 S/SPC	 33/38	 (86.8)	
Imipenem/Cilastatin	 S/SPC	 5/5	 (100)	
Tigecycline	 S/SPC	 38/38	 (100)	
Clarithromycin	 S/SPC	 63/64	 (98.4)	
Clindamycin	 S/SPC	 62/64	 (96.8)	
Vancomycin	 S/SPC	 32/63	 (50.8)	
Teicoplanin	 B	 34/59	 (57.6)	
Linezolid	 S/SPC	 60/62	 (96.7)	











	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Country	 	 	 	 	 	 	 	
	 England	 16	 	 27	 14	 	 1	 0.129	
	 Scotland	 	 	 5	 	 	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 1	 	 	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 For	details	see	table	7a	 0.017	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 5	 	 6	 3	 	 	 0.177	
10	–	20		 6	 	 17	 8	 	 	 	
>20		 5	 	 3	 3	 	 1	 	
Not	known	 1	 	 6	 	 	 	 	
AfC	band	 	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.028	
	 7	 	 	 6	 	 	 	 	
	 8a	 12	 	 13	 5	 	 1	 	
	 >8b	 5	 	 13	 9	 	 	 	
How	long	have	you	been	working	in	Critical	Care	(years)	
	 	 	 	
	 <1	 	 	 2	 	 	 	 0.604	
	 1-5	 5	 	 5	 1	 	 	 	
	 6-10	 5	 	 10	 4	 	 	 	
	 >10	 7	 	 15	 9	 	 1	 	
Does	the	CCU	have	pharmacist	cover	
	 	 	 	 	 	
	 Never	 	 	 	 	 	 	 <0.001	
Rarely/ad	hoc	 1	 	 	 	 	 	 	
	 Weekdays	 15	 	 31	 5	 	 1	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	
	 Everyday	 1	 	 1	 9	 	 	 	
Does	the	pharmacist	generally	attend	the	ward	round	
	 	 	 	
	 Yes	 12	 	 23	 11	 	 1	 0.820	
	 No	 5	 	 9	 3	 	 	 	
Does	the	CCU	have	regular	ward	rounds	with	the	microbiologist	
	 	 	 	
7	days	a	week	 2	 	 3	 4	 	 1	 0.031	
Monday	to	Friday	 9	 	 22	 10	 	 	 	
Weekly	 6	 	 7	 	 	 	 	
	 No	 	 	 	 	 	 	 	

















	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Which	country	 	 	 	 	 	 	 	
	 England	 25	 4	 16	 13	 	 	 0.556	
	 Scotland	 3	 	 2	 	 	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 1	 	 	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 	 For	details	see	table	7a	 	 	 0.089	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 6	 	 5	 3	 	 	 0.424	
10	–	20	 14	 1	 8	 8	 	 	 	
>20	 6	 2	 2	 2	 	 	 	
Not	known	 3	 1	 3	 	 	 	 	
AfC	band	 	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.056	
	 7	 2	 	 4	 	 	 	 	
	 8a	 18	 1	 8	 4	 	 	 	
	 >8b	 9	 3	 6	 9	 	 	 	
How	long	have	you	been	working	in	Critical	Care	(years)	
	 	 	 	 	
	 <1	 	 	 2	 	 	 	 0.521	
	 1-5	 5	 1	 4	 1	 	 	 	
	 6-10	 10	 1	 5	 3	 	 	 	
	 >10	 14	 2	 7	 9	 	 	 	
Does	the	CCU	have	pharmacist	cover	
	 	 	 	 	 	
	 Never	 	 	 	 	 	 	 <0.001	
Rarely/ad	hoc	 	 	 1	 	 	 	 	
	 Weekdays	 28	 4	 16	 4	 	 	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	
	 Everyday	 1	 	 1	 9	 	 	 	
Does	the	pharmacist	generally	attend	the	ward	round	
	 	 	 	
	 Yes	 23	 1	 13	 10	 	 	 0.194	
	 No	 6	 3	 5	 3	 	 	 	
Does	the	CCU	have	regular	ward	rounds	with	the	microbiologist	
	 	 	 	
7	days	a	week	 5	 	 1	 4	 	 	 0.087	
Monday	to	Friday	 16	 3	 13	 9	 	 	 	
Weekly	 8	 1	 4	 	 	 	 	
	 No	 	 	 	 	 	 	 	

















	 	 B	 S/B	 S/SPC	 EII	 CI	 N/A	 P-value§	
Which	country	 	 	 	 	 	 	 	
	 England	 	 	 30	 	 27	 1	 0.455	
	 Scotland	 	 	 1	 	 4	 	 	
	 Wales	 	 	 	 	 	 	 	
Northern	Ireland	 	 	 1	 	 	 	 	
CCN/Region	 	 	 	 	 	 	 	
	 	 For	details	see	table	7a	 	 	 0.154	
Size	of	CCU	(no.	beds)	 	 	 	 	 	 	 	
<10	 	 	 10	 	 4	 	 0.580	
10	–	20	 	 	 14	 	 16	 1	 	
>20	 	 	 5	 	 7	 	 	
Not	known	 	 	 3	 	 4	 	 	
AfC	band?	 	 	 	 	 	 	
	 6	 	 	 	 	 	 	 0.142	
	 7	 	 	 3	 	 3	 	 	
	 8a	 	 	 20	 	 11	 	 	
	 >8b	 	 	 9	 	 17	 1	 	
How	long	have	you	been	working	in	Critical	Care	(years)	 	 		 	 	
	 <1	 	 	 1	 	 1	 	 0.291	
	 1-5	 	 	 7	 	 4	 	 	
	 6-10	 	 	 12	 	 6	 1	 	
	 >10	 	 	 12	 	 20	 	 	
Does	the	CCU	have	pharmacist	cover	 	
	 	 	 	 	
	 Never	 	 	 	 	 	 	 0.109	
Rarely/ad	hoc	 	 	 1	 	 	 	 	
	 Weekdays	 	 	 29	 	 22	 1	 	
Weekdays	&	Saturdays	 	 	 	 	 	 	 	




	 Yes	 	 	 19	 	 27	 1	 0.030	




7	days	a	week	 	 	 3	 	 7	 	 0.342	
Monday	to	Friday	 	 	 20	 	 20	 1	 	
Weekly	 	 	 9	 	 4	 	 	
	 No	 	 	 	 	 	 	 	









































































make	 sure	 the	 results	 yielded	 are	 both	 valid	 and	 reliable.	 Validity	 refers	 to	 the	 accuracy	 of	 the	
measurement	i.e.	does	the	questionnaire	ask	the	right	questions	to	meet	the	aims	of	the	study.	Are	
any	 key	 subjects	missed/excluded.	Can	 the	 results	be	generalised	 to	 the	wider	UK	CCU	population.	
Reliability	refers	to	the	consistency	of	the	measurement	i.e.	the	degree	to	which	the	questions	used	





26.2%	 of	 UK	 CCUs	 responded	 to	 this	 questionnaire.	 What	 constitutes	 a	 “good”	 or	 “adequate”	
response	rate	is	much	debated	and	there	does	not	appear	to	be	a	clear	answer.	The	annual	Faculty	of	
Intensive	Care	Medicine	(FICM)	survey	of	the	critical	care	consultant	workforce	over	a	4	year	period	
between	 2010	 and	 2014	 has	 had	 a	 response	 rate	 varying	 between	 40	 and	 50%	 (The	 Faculty	 of	
Intensive	Care	Medicine,	2015).	Response	rates	in	general	to	questionnaires	circulated	by	the	UKCPA	
are	generally	between	10	and	20%	 (Carter,	2015).	 This	 rate	 is	however	 lower	 than	other	published	
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surveys	 involving	 specifically	 critical	 care	 pharmacist	 members	 of	 the	 UKCPA	 (Yassin	 et	 al.,	 2014;	
Bourne,	2015),	both	of	which	had	response	rates	of	approximately	60%.	These	surveys	 investigated	
UK	 practice	 via	 the	 UKCPA	 CCG	 message	 board	 but	 had	 active	 follow	 up	 of	 non-responders	 by	





the	 time	 the	 questionnaire	 was	 posted	 and	 the	 time	 required	 to	 complete	 the	 questionnaire,	 the	
participant	 information	 sheet	 gave	a	 guide	 time	of	15	minutes,	may	have	adversely	 influenced	 this	
overall	response	rate.	Another	potential	problem	associated	with	all	questionnaires	conducted	in	this	
manner	 is	 the	 risk	of	 convenience	 sampling	 and	 its	 associated	bias.	 Convenience	 sampling	 involves	
selecting	 subjects	 because	 of	 their	 convenient	 accessibility	 and	 risks	missing	 those	 that	 don’t	 have	
access	 to	 the	 questionnaire,	 in	 this	 case	 critical	 care	 pharmacists	 that	 were	 not	 members	 of	 the	
UKCPA	CCG.	Hopefully	this	will	have	had	little	biasing	effects	on	the	overall	results,	as	there	are	many	
more	 pharmacists	 registered	 with	 the	 message	 board	 than	 there	 are	 CCUs	 in	 the	 UK.	 There	 is	
currently	no	way	of	determining	if	the	pharmacist	on	any	given	CCU	is	also	a	member	of	the	UKCPA	
CCG	but	 a	 recent	workforce	 survey	 showed	 that	 only	 2%	of	 CCUs	where	without	pharmacist	 cover	






for	 80.3%	 (196/244)	 of	 the	 UK	 total	 as	 listed	 by	 ICNARC	 and	 SICSAG.	 This	 geographical	 split	 is	
consistent	 with	 that	 reported	 in	 the	 previously	 mentioned	 UK	 studies	 with	 higher	 total	 response	




the	 demographics	 of	 the	 membership	 of	 the	 UKCPA	 CCG,	 i.e.	 it	 may	 be	 that	 the	 members	 are	
predominantly	 based	 in	 England.	 Alternatively,	 as	 previously	 discussed,	 it	 may	 reflect	 the	 level	 of	




of	 critical	 care	 services	 across	 a	 geographical	 area),	 review	 the	 geography	 of	 the	 responses	 and	
although	most	 regions/CCNs	 are	 represented	 in	 the	 responses	 some	 areas	 have	 a	 higher	 response	
rate	than	others,	namely	my	own	CCN	and	those	neighbouring	 in	the	North	West	of	England.	Again	
this	may	reflect	the	level	of	interest	locally	in	the	subject	rather	than	people	responding	because	they	
know	 the	 investigator.	 Another	 possible	 reason	 for	 variation	 is	 that	 some	CCUs	may	not	 have	CCU	
pharmacists	 and	 this	may	 be	 not	 just	 an	 individual	 hospital	 problem	 but	 also	 a	 regional/CCN	 one.	
Although	a	recent	workforce	survey	showed	that	only	2%	of	UK	CCUs	are	currently	without	a	critical	
care	 pharmacist,	 many	 pharmacists	 do	 not	 class	 themselves	 as	 specialists	 and	 may	 not	 have	 felt	
confident	responding.		
	
93.7%	 of	 respondents	 described	 their	 CCU	 as	 a	 general/mixed	 unit;	 this	 is	 consistent	 with	 other	
published	surveys	of	CCUs,	for	example	91.7%	in	Yassin	et	al	(Yassin	et	al.,	2014),	and	implies	that	the	












studies	 involving	 critical	 care	pharmacists,	 e.g.	 Yassin	et	al	 reported	>85%	 (Yassin	et	al.,	 2014),	 and	
seems	 to	 show,	 along	 with	 previously	 mentioned	 points,	 that	 the	 respondents	 are	 a	 cohort	
representative	of	the	current	critical	care	pharmacist	workforce..		
	
50%	 of	 responding	 pharmacists	 had	 greater	 than	 10	 years	 experience	 working	 in	 critical	 care,	
approximately	 80%	 had	 more	 than	 5	 years	 and	 only	 3.1%	 had	 less	 than	 a	 years	 experience.	 Any	








role.	 Approximately	 4/5th	 (81.3%)	 of	 CCUs	 had	weekday	 pharmacist	 visits,	 1/5th	 (17.2%)	 had	 a	 visit	
everyday	and	1	CCU	had	only	an	ad-hoc	service.	No	responding	pharmacists	suggested	that	their	CCU	
had	 no	 cover	 although	 it	 is	 thought	 that	 about	 2%	 of	 UK	 CCUs	 still	 have	 no	 pharmacist	 input	
(Borthwick	 et	 al.,	 2018).	 It	 is	 proposed	 that	 the	 reason	 this	 later	 point	 is	 not	 reflected	 in	 the	
questionnaire	responses	is	two-fold.	Firstly	the	target	audience	was	pharmacists	who	were	members	
of	 the	UKCPA	CCG	who	would	tend	to	be	working	 in	critical	care	but	 this	 isn’t	necessarily	 true	 (e.g.	
some	 UKCPA	members	 sign	 up	 to	 all	 of	 the	 message	 boards).	 The	 second	 reason	 is	 that	 the	 first	
question	 asked	 if	 the	 respondent	was	 currently	working	 in	 critical	 care;	 if	 they	 answered	 “no”	 the	
questionnaire	stopped	at	that	point.	A	limitation	to	be	considered	when	analysing	practice	compared	









Approximately	75%	of	 responding	pharmacists	 stated	 that	 they	 generally	 attend	 the	 consultant	 led	
ward	round.	Ward	round	attendance	 in	this	study	has	been	used	as	a	 further	marker	of	pharmacist	
involvement	in	the	“Critical	Care	Team”.	It	is	an	indication	that	the	pharmacist	who	attends	the	ward	


























To	 date,	 methods	 of	 administration	 which	 are	 being	 commonly	 used	 on	 UK	 CCUs	 have	 not	 been	
adequately	 evaluated.	 As	 previously	 discussed,	 a	 literature	 review	 at	 the	 time	 of	 inception	 of	 the	
study	 found	no	UK	or	 international	 studies	of	current	practice	 in	CCUs.	 In	 the	 intervening	 time	one	
international	 study	 has	 been	 published	 (Tabah	 et	 al.,	 2015).	 This	 study,	 an	 international	 survey	
published	in	2015	but	conducted	in	2013	at	a	similar	time	to	my	own	survey,	investigated	practices	of	
antimicrobial	dosing	and	monitoring	in	existence	in	Intensive	Care	Units	(ICU)	around	the	world	with	




is	 therefore	stated	 in	the	Summary	of	Product	Characteristics	 (SPC).	 In	 line	with	this,	where	a	given	





in	 the	 SPC.	 For	 the	 remaining	 5	 antibiotics	 practice	was	 largely	 split	 across	 2	 licensed	methods	 of	
administration	leading	to	neither	one	coming	out	as	a	clear	favourite.	For	example	the	SPC	for		
benzylpenicillin	 states	 that	 it	 can	be	administered	either	as	a	bolus	 injection	or	as	a	 short	 infusion.	
40.8%	of	respondents	usually	gave	as	a	bolus,	35.5%	as	a	short	 infusion	and	9.7%	a	combination	of	
both	 dependent	 on	 the	 dose	 being	 administered.	 This	 factor	 can	 also	 be	 seen	 even	 where	 usual	








that	one	practice.	Ciprofloxacin,	 linezolid,	 tigecycline,	 tiracillin/clavulanic	acid	and	clarithromycin	all	
have	very	specific	methods	of	administration	stipulated	and	little	or	no	evidence	in	the	literature	to	
suggest	or	support	deviation	 from	the	 license	so	unsurprisingly	all	have	standard	practice	reflecting	




















of	 benzylpenicillin	 and	 flucloxacillin.	 These	 two	 Trusts	 combined	 accounted	 for	 all	 EII	 practice	 of	
ceftazidime	(see	table	3.4).	Counting	CCUs	separately	 rather	 than	analysing	the	results	by	Trust	has	
led	to	an	inflated	appearance	in	some	of	the	values,	for	example	16%	(8/49)	of	CCUs	give	ceftazidime	
as	 an	 EII	 but	 this	 equates	 to	 only	 5%	 of	 Trusts	 (2/37).	 CCUs	 were	 counted	 separately	 to	 identify	
differences	between	specialties	e.g	medical	units	versus	surgical	or	cardiothoracic,	as	well	as	between	
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lactam	 antibiotics,	 it	 exhibits	 slow	 time	 dependent	 kill	 (Löwdin	 et	 al.,	 1998)	 however	 it	 has	 a	
moderately	 long	 post-antibiotic	 effect,	 unlike	 β-lactams	 and	more	 like	 an	 aminoglycoside,	meaning	
the	time	spent	above	the	MIC	becomes	less	relevant	(Moise-Broder	et	al.,	2004).	More	recently	it	has	
been	suggested	 that	 the	most	 important	parameter	 is	actually	MIC/AUC	 (Holmes	et	al.,	 2013).	This	
uncertainty	 didn’t	 stop	 investigators	 as	 early	 as	 the	 1980s	 looking	 into	 the	 efficacy	 of	 continuous	
infusions	 (Barois	 et	 al.,	 1986;	 Brinquin	 et	 al.,	 1993);	 these	 early	 studies,	 although	 small,	 showed	
consistent	achievement	of	target	 levels,	clinical	cure	and,	 in	one	study,	no	increase	in	renal	toxicity.	
Possibly	the	best	and	most	referenced	study	conducted	to	date	was	published	in	2001.	Marc	Wysocki	








this	 effect	may	be	due	 to	higher	peak	 concentrations	 associated	with	high	 troughs	 rather	 than	 the	
trough	itself	but	it	is	none	the	less	of	concern	as	published	CI	protocols	target	levels	of	15	–	25mg/L		
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In	 light	 of	 the	 lack	 of	 definitive	 evidence	 to	 support	 the	 use	 of	 CIs	 over	 licensed	 methods	 of	
administration	it	is	possibly	surprising	to	see	that	approximately	half	of	responding	CCUs	(49.2%)	have	
adopted	CIs	as	their	standard	practice.	Of	all	the	factors	investigated,	only	pharmacist	attendance	on	
the	 ward	 round	 seemed	 to	 significantly	 influence	 the	 choice	 of	 method	 of	 administration	 of	
vancomycin	 (see	 table	 3.8,	 p=0.03).	 Simply	 attending	 the	 ward	 to	 review	 patient	 charts	 had	 no	
influence	on	choice	(p=0.109).	This	potentially	implies	that	the	level	of	involvement	of	the	pharmacist	
in	 the	 wider	 team	may	 influence	 administration	 choice	 but	 other	 factors	 such	 as	 grade	 and	 years	
experience	 that	may	 similarly	 but	more	 weakly	 correlate	 to	 input	 did	 not	 show	 this	 (p=0.142	 and	
0.291	respectively).	With	vancomycin	the	significance	is	possibly	more	clear-cut	than	in	the	cases	of	
piperacillin/tazobactam	 and	meropenem.	 It	 involved	 comparing	 the	 usage	 of	 just	 two	methods	 of	
administration	rather	than	three	or	four	i.e.	short	infusion	to	that	of	CIs	and	so	is	likely	to	be	a	truly	
significant	factor.	With	the	exception	of	microbiologist	input	and	CCN/region,	these	data	suggest	that	
where	EIIs/CIs	are	used	as	usual	practice	 the	pharmacist	 is	experienced	and	an	 integral	member	of	
the	 CCU	 team.	 In	 only	 a	 small	 group	 of	 instances	 did	 a	 patient	 orientated	 factor	 affect	 choice	 of	




2015).	Therapeutic	drug	monitoring	 (TDM)	was	used	to	guide	 therapy	 in	all	CCUs	using	vancomycin	







Both	 piperacillin	 and	 meropenem	 fit	 into	 a	 wider	 class	 of	 antibiotics	 referred	 to	 β-lactams	 that	
includes	 all	 penicillins,	 cephalosporins	 and	 carbopenems.	 Both	 the	 pharmacokinetics	 and	
pharmacodynamics	have	been	well	described	for	the	β-lactams	as	a	whole	(Craig,	1998;	Lodise	et	al.,	
	 70	
2006)	 and	 when	 piperacillin/tazobactam	 and	 meropenem	 (Nicolau,	 2008)	 have	 been	 investigated	
they	 have	 fitted	 with	 previous	 finding	 for	 the	 class	 as	 a	 whole.	 The	 β-lactams	 all	 exhibit	 a	 slow	
continuous	 kill	 that	 is	 related	 almost	 entirely	 to	 the	 time	 spent	 above	 the	 minimum	 inhibitor	








or	 the	 use	 of	 EIIs/CIs	 have	 been	 suggested	 as	 ways	 of	 improving	 clinical	 outcome	 and	 reducing	
resistance	(Felton	et	al.,	2013;	Abdul-Aziz	et	al.,	2015).	
	
The	popularity	 of	 these	 two	agents	 in	 particular	 has	 lead	 to	 their	methods	of	 administration	being	
much	studied.	They	are	both	currently	licensed	to	be	administered	as	short	infusions	with	a	suggested	
duration	of	30	minutes.	Meropenem	 is	also	 licensed	 to	be	administered	as	a	bolus	 injection	over	5	
minutes.	Advice	to	bolus	piperacillin/tazobactam	was	removed	from	the	UK	SPC	in	2011	to	bring	it	in	
line	with	the	rest	of	the	EU	where	it	is	only	licensed	to	be	given	by	short	infusion,	the	reason	stated	
was	 harmonisation	 (european	 medicines	 agency,	 2011).	 There	 are	 now	 many	 papers	 and	 review	
articles	suggesting	the	pk/pd	benefits	of	CIs	and	EIIs	of	these	two	agents	(Roberts	et	al.,	2008b;	Abdul-




EII,	 and	none	of	 the	 respondents	 currently	 use	 continuous	 infusions	of	 either	drug.	 This	 pattern	of	
usage	 reflects	 the	 literature;	 whilst	 there	 are	 plenty	 of	 papers	 touting	 the	 potential	 benefits	 of	
extended	infusion	periods,	until	recently	(post	the	questionnaire),	these	all	report	use	of	3-	or	4-hour	
EIIs	 rather	 than	CIs.	CIs	have	 the	disadvantage	of	 tying	up	an	 intravenous	 line	24	hours	a	day	 for	a	
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tables	 3.6	 and	 3.7).	 With	 both	 piperacillin/tazobactam	 and	 meropenem	 on	 CCUs	 where	 the	
pharmacist	 reviewed	patients	on	weekdays	only	 they	were	more	 likely	 to	use	either	bolus	or	 short	
infusions	(92%	and	90%	respectively)	whereas	on	the	CCUs	with	a	daily	visit	EIIs	were	more	common	
(both	 82%).	 Although	 this	 result	 was	 highly	 significant	 and	 11	 of	 the	 62	 responding	 CCUs	 have	 a	
pharmacist	visit	every	day	this	actually	only	accounts	for	4	of	the	52	responding	Trusts	(2	Trusts	with	
everyday	visits	had	4	 responding	CCUs	each).	 There	were	other	 factors	 seeming	 to	affect	 choice	of	
administration	method	for	both	piperacillin/tazobactam	and	meropenem.	The	higher	the	pharmacist	















certain	 circumstances	 they	would	use	 them	 (see	 tables	 3.9	 and	3.10).	 The	 reasons	 stated	 could	be	
split	into	two	categories.	The	first	would	be	classed	as	patients	with	conditions	that	are	perceived	to	
have	significantly	altered	the	pk/pd	parameters	such	as	septic	shock	and	major	burn	 injury.	Both	of	
these	 conditions	 cause	 an	 increase	 in	 volume	 of	 distribution	 and	 an	 increase	 in	 renal	 clearance	 of	
water	 soluble,	 low	 protein	 bound	 drugs	 such	 as	 the	 β-lactams	 being	 discussed	 (Shah	 et	 al.,	 2015).	
Multiple	 studies	 have	 shown	 drug	 levels	 to	 be	 altered	 in	 these	 patient	 groups	 (Weinbren,	 1999;	
Roberts	 et	 al.,	 2011a;	 Udy	 et	 al.,	 2015)	 and	 some	 have	 shown	 that	 EIIs	 or	 CIs	 lead	 to	 a	 more	
favourable	pk/pd	profile	(De	Waele	et	al.,	2014).	It	is	therefore	logical	that	prescribers	may	target	the	
patients	who	 are	 likely	 to	 gain	 the	most	 from	 these	 practices.	 The	 second	 category	 is	 in	 targeting	
organisms	that	have	the	highest	MICs	and	therefore	require	high	concentrations	of	antimicrobial	at	
the	target	site;	2	CCUs	used	EIIs	of	piperacillin/tazobactam	and	meropenem	solely	for	the	treatment	
of	 Pseudomonas	 spp.	 which	 have	 a	 high	 MIC	 and	 are	 noted	 for	 high	 treatment	 failure	 rates	 and	
development	of	resistance	(McCarthy,	2015).	Many	studies	investigating	EIIs	of	β-lactams	exploit	their	







31	 out	 of	 62	 respondents	 stated	 that	 the	 driving	 force	 was	 the	 published	 evidence	 on	 the	 pk/pd	
benefits	 of	 EIIs	 and	 CIs,	 with	 26	 stating	 that	 they	 considered	 the	 evidence	 showed	 improved	
outcomes	 -	 however,	 currently	 it	 is	 difficult	 to	 fully	 agree	 with	 this	 and	 perhaps	 indicates	 some	
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pharmacists	 may	 have	 only	 a	 superficial	 grasp	 of	 the	 evidence.	 13	 respondents	 reported	 reduced	
toxicity,	 specifically	 of	 vancomycin,	 as	 a	 driving	 force.	 Here	 the	 general	 opinion	 was	 that	 CIs	 of	
vancomycin	 are	 more	 convenient	 –	 easier	 for	 the	 nursing	 staff	 to	 manage,	 easier	 to	 adjust,	 with	




USA,	 reporting	 lower	 total	daily	doses	being	required	were	EIIs/CIs	are	used	 it	 is	perhaps	surprising	
more	respondents	didn’t	mention	this	as	a	consideration.	One	study	explored	using	a	loading	dose	of	
4.5g	piperacillin/tazobactam	followed	by	a	CI	of	9g	per	day	rather	than	the	licensed	dose	of	4.5g	three	





TDM	 is	universally	 carried	out	 for	aminoglycosides	 (such	as	gentamicin)	 and	glycopeptides	 (such	as	
vancomycin).	 This	 is	 no	 surprise	 as	 in	 the	UK	 as	 TDM	 is	 a	 part	 of	 standard	 care	when	 using	 these	
antibiotics	 due	 to	 their	 nephrotoxic	 and	 ototoxic	 nature	 and	 narrow	 therapeutic	 drug	 index	 (the	
window	of	serum	level	where	the	drug	is	effective	but	not	toxic)	and	more	recently	with	vancomycin	
to	make	sure	the	serum	level	 is	consistently	above	the	MIC.	A	recent	international	survey	(Tabah	et	
al.,	 2015)	asked	a	 similar	question	but	 found	 that	many	centres	outside	 the	UK	don’t	do	any	TDM,	
20%	of	respondents	did	no	gentamicin	 levels	and	a	further	19%	only	did	 levels	 if	 the	patient	was	 in	
renal	failure.	Where	there	does	seem	to	be	some	disconnect	within	UK	practice	though	is	in	the	fact	
that	 although	 75%	 of	 those	 using	 EIIs/CIs	 profess	 to	 be	 doing	 so	 for	 pk/pd	 reasons	 no	 one	 is	
measuring	serum	levels	of	the	other	commonly	use	drug,	piperacillin/tazobactam	or	meropenem.	This	









the	 future	 as	preserving	 the	 existing	 antibiotics	we	have	available	 to	use	becomes	more	 and	more	





In	 conclusion,	 common	 intravenous	 administration	 practices	 exist	 for	 most	 antibiotics	 used	 in	 UK	
CCUs.	 CCUs	 tended	 to	 follow	 licensed	 methods	 of	 administration	 and	 where	 there	 was	 no	 usual	
practice	 this	 was	 because	 there	 was	 a	 split	 in	 responses	 across	 multiple	 licensed	 methods	 of	
administration.	






method	 of	 administration	 than	 intermittent	 infusions.	 Where	 extended	 infusions	 were	 in	 use	 this	
practice	was	associated	with	a	high	level	of	pharmacist	input	into	the	multi	professional	team	such	as	
seven-day	 ward	 cover.	 Although	 these	 unlicensed	 methods	 are	 widespread	 there	 is	 still	 limited	
evidence	 showing	 any	 patient	 benefit,	 such	 as	 reduced	 length	 of	 CCU	 stay,	 and	 none	 showing	






safety	 of	 extended	 versus	 intermittent	 infusions	 of	 antibiotics	 in	 adult	
patients	with	sepsis		
4.1	 Introduction	














controlled	 trials	 in	 humans	 exploring	 the	 pharmacokinetic	 and	 pharmacodynamics	 parameters	
associated	with	continuous	and	intermittent	infusions	of	time-dependent	kill	antibiotics	(Kasiakou	et	
al.,	2005a).	As	might	be	expected,	where	reported,	the	maximum	serum	concentration	(Cmax)	in	the	
intermittent	 infusion	 groups	 was	 higher	 than	 the	 steady	 state	 concentration	 in	 the	 continuous	












on	 individual	 agents	 such	 as	 meropenem	 (Yu	 et	 al.,	 2018).	 Many	 of	 these	 reviews	 selected	
randomised	controlled	trials	only	but	a	number	have	also	included	cohort	studies	(Chant	et	al.,	2013;	
Falagas	et	al.,	2013;	Lal	et	al.,	2016).	Reviewers	have	tended	to	focus	on	studies	investigating	septic	
patients	 as	 a	whole,	 but	 some	 have	 chosen	 specific	 patient	 groups	 such	 as	 those	with	 nosocomial	
pneumonia	(Lal	et	al.,	2016).	A	2016	review	(Roberts	et	al.,	2016)	had	very	specific	 inclusion	criteria	







On	 the	whole,	many	 of	 these	 reviews	 have	 found	 improved	 clinical	 cure	 or	 reduced	 clinical	 failure	







that	 many	 papers	 in	 earlier	 reviews	 are	 3	 or	 4	 decades	 old,	 have	 small	 patient	 numbers	 and	 use	
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antibiotics	that	are	rarely,	if	ever,	used	today.	Whilst	these	studies	are	still	of	value	in	a	meta-analysis,	
the	 last	decade	has	seen	a	number	of	much	 larger	and	perhaps	more	relevant	studies.	Most	of	 the	
more	 recent	 publications	 follow	 the	 internationally	 accepted	 guidance	 on	 the	 preparation	 and	
















Open	 label	 or	 blinded	 parallel	 group	 randomised	 controlled	 trials	 (RCTs)	 comparing	 extended	 and	
intermittent	intravenous	administration	of	the	same	antibiotic	were	selected	for	review.	Studies	were	










Extended	 intravenous	 administration	 includes	 extended	 (for	 example	 over	 3	 or	 4	 hours)	 and	









persistent	 or	 significant	 disability	 or	 incapacity,	 is	 another	 condition	 that	 investigators	
judge	to	represent	significant	harm/hazard)	
Secondary	outcomes	











al.,	 2015)	 and	 registered	 on	 the	 PROSPERO	 website	 (www.crd.york.ac.uk/PROSPERO/).	 These	 two	
processes	 dovetail	 together	 to	 support	 the	 development	 of	 reproducible	 and	 robust	 systematic	
reviews	and	meta-analyses.		
Many	published	studies	recorded	a	measure	of	positive	clinical	response,	for	example	a	combination	
of	 clinical	 cure	 and	 clinical	 improvement.	 This	was	 reported	 either	 alone	 or	with	 clinical	 cure.	 This	
outcome	measure	was	added	during	data	extraction.	In	some	instances	authors	reported	a	composite	
of	 cure	and	 improvement	as	 “clinical	 cure”	 for	 the	purpose	of	 the	meta-analysis	 this	was	 recorded	
and	analysed	as	“clinical	 response”	 in	 line	with	 the	definition	of	 this	 in	other	articles.	Some	articles	
reported	“clinical	 failure”	 i.e.	a	 lack	of	cure	or	 improvement,	where	the	data	was	unambiguous	and	
















example	 antibiotic*)	 and/or	 hyphenated	 (for	 example	 anti-bacterial).	 Initial	 searches	 were	 not	
restricted	by	any	limits,	for	example,	to	participant	age,	date	or	language.	
The	searches	were	further	refined	by	applying	the	search	strategy	suggested	in	“The	Cochrane	Highly	
Sensitive	 Search	 Strategies	 for	 identifying	 randomised	 trials”	 (Higgins	 and	 Green,	 2011a).	 This	 was	
developed	to	 identify	 randomised	 trials	 in	Medline	but	has	also	been	adapted	 for	use	with	Embase	
(Higgins	 and	 Green,	 2011b).	 The	 Cochrane	 handbook	 offers	 two	 versions:	 a	 sensitivity-maximising	
version	 and	 a	 sensitivity-	 and	 precision-maximising	 version;	 the	 sensitivity-maximising	 version	 was	
used	in	these	searches.	
Following	 this,	 restrictions	were	 applied	 to	 remove	 animal	 studies	 and	 focus	 the	 results	 on	human	
adults.	References	from	relevant	papers	were	also	be	reviewed,	as	was	the	investigator’s	own	library.	
Expert	 opinion	 was	 sought	 to	 identify	 other	 papers	 including	 those	 in	 press	 or	 RCTs	 likely	 to	 be	
published	in	the	very	near	future.	
In	April	2018	the	search	was	updated	by	re-running	the	database	searches	as	described	above.	Some	
terms	 and	 abbreviations	 within	 Athens	 had	 changed	 since	 the	 original	 search	 so	 this	 search	 was	
modified	to	take	this	into	account.	A	final	step	was	added	to	restrict	the	results	at	this	stage	to	2015	









and	 selecting	 every	 5th	 title/abstract	 for	 review	by	ML.	 Any	 discrepancies	 between	 reviewers	were	
resolved	 by	 re-review	 of	 those	 studies	 until	 agreement	 was	 reached.	 Studies	 not	 meeting	 the	
inclusion	criteria	as	defined	a	priori	were	excluded.	Studies	meeting	the	inclusion	criteria	were	further	
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examined,	 full	 texts	were	 retrieved	 and	where	 possible	 English	 translations	 obtained.	GB	 reviewed	
these	studies	and	the	reason	for	rejection	at	this	point	was	recorded.	If	data	from	a	study	had	been	
published	 on	 more	 than	 one	 occasion	 then	 care	 was	 taken	 to	 ensure	 that	 outcomes	 were	 only	
included	once	and	that	all	publications	were	referenced	for	the	study.		
4.3.4.2	 Data	extraction	







































The	unit	of	analysis	used	was	 the	patient	participant	and	data	 from	each	 randomized	patient	were	












The	 I2	 statistic	 has	 been	 used	 as	 the	 main	 measure	 of	 heterogeneity.	 Heterogeneity	 should	 be	

















of	 work,	 antibiotics	 with	 significant	 UK-wide	 usage	 as	 extended	 infusions	 were	 also	 analysed	
individually.	In	articles	that	reported	investigating	antibiotics	by	general	class,	e.g.	β-lactams,	and	data	




Specifics	 of	 the	 sensitivity	 analysis	 were	 not	 defined	 a	 priori	 but	 were	 performed	 on	 primary	
outcomes	and	any	outcomes	yielding	a	significant	result.	Sensitivity	analysis	was	conducted	to	assess	




The	 initial	 database	 search	 conducted	 in	 June	 2016	 identified	 6190	 articles	 with	 an	 additional	 2	
articles	 being	 identified	 from	 other	 sources.	 After	 removal	 of	 duplicates	 4255	 articles	 remained.	
Titles,	 and	 where	 appropriate	 abstracts,	 of	 these	 articles	 were	 screened	 and	 4196	 articles	 were	










article	 coming	 from	 other	 sources.	 After	 removal	 of	 duplicates	 439	 articles	 remained	 and	 after	


























































































































































Forty	 articles	 were	 included	 in	 the	 meta-analysis,	 34	 investigating	 continuous	 infusions	 and	 6	
extended	 infusions.	 The	 studies	 ranged	 in	 size	 from	 10	 to	 422	 patients,	 with	 a	 mean	 size	 of	 85	
patients	 (median	 50)	 and	 10	 articles	 reported	 on	 studies	 containing	 at	 least	 100	 patients.	 The	
systematic	 review	 contained	 a	 combined	 total	 of	 more	 than	 3300	 patients.	 All	 included	 articles	
investigated	adults	over	the	age	of	18	exclusively	with	the	exception	of	two	(Feld	et	al.,	1977;	Wright	
et	al.,	1979).	The	age	range	across	the	studies	was	11	to	102	years	old.	One	article	(Feld	et	al.,	1977)	
stated	 no	 age	 range	within	 their	 inclusion/exclusion	 criteria	 but	 included	 patients	 of	 15	 and	 over,	
however	as	the	median	age	was	43	to	46	years	old,	the	study	was	included	as	it	was	deemed	that	the	
number	of	patients	under	18	would	have	been	small.	One	article	(Wright	et	al.,	1979)	again	did	not	
specify	 within	 the	 inclusion/exclusion	 criteria	 that	 patients	 must	 be	 over	 18	 years	 old	 but	 the	
documented	age	ranges	in	both	the	pneumonia	and	shock	lung	groups	are	11-69	(mean	44)	and	11-55	
(mean	33)	years	old	respectively.	The	article	by	Bao	et	al	stated	in	their	inclusion	criteria	an	upper	age	




were	 there	more	 females	 than	male	 participants.	 Two	 articles	 did	 not	 state	 the	male/female	 split	
(Wright	et	al.,	1979;	Lipman	et	al.,	1999).	
Antibiotics	 studied	 included	piperacillin	 (+/-	 tazobactam)	 (number	of	 articles	 =	 14),	 ceftazidime	 (9),	
meropenem	 (7),	 cefepime	 (2),	 temocillin	 (2),	 ticarcillin-clavulanate	 (2),	 tobramycin	 (2),	 vancomycin	
(2),	 cefamandole	 (1),	 cefoperazone	 (1),	 cefotaxime	 (1),	 ceftriaxone	 (1),	 gentamicin	 (1),	 imipenem-
cilastatin	 (1),	 linezolid	 (1),	sisomicin	 (1).	A	number	of	studies	 investigated	more	than	one	antibiotic,	




In	 24	 articles	 the	 use	 of	 non-study	 antibiotics	 was	 not	 documented	 nor	 was	 it	 clear	 whether	
concomitant	 use	 of	 non-study	 antibiotics	 was	 allowed.	 Two	 studies	 stated	 the	 use	 of	 non-study	
antibiotics	in	the	exclusion	criteria	(Lubasch	et	al.,	2003;	Lau	et	al.,	2006).	The	remaining	14	articles	all	
allowed	 the	 use	 of	 additional	 open	 label	 antibiotics	 during	 the	 study	 but	 with	 varying	 levels	 of	
restrictions.	Bao	et	al	 (Bao	et	al.,	2017)	allowed	their	use	but	counted	their	use	as	a	sign	of	clinical	
failure	when	assessing	clinical	outcome.	Fan	et	al.	 (Fan	et	al.,	2017)	excluded	concomitant	β-lactam	
use	 but	 allowed	 all	 other	 antibiotics.	Most	 articles	 stated	 they	were	 allowed	 but	 did	 not	 allude	 to	
which	 antibiotics	 had	 been	 used	 and	 in	 how	 many	 patients.	 Two	 studies	 listed	 the	 antibiotics	
prescribed	and	assessed	for	statistically	significant	differences	between	treatment	and	control	groups	
(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016).	
Seven	articles	 included	 in	 the	systematic	 review	contributed	no	data	 to	 the	meta-analysis.	Three	of	
these	 articles	 did	 not	 present	 any	 outcomes	 relevant	 to	 the	 meta-analysis	 (Lipman	 et	 al.,	 1999;	


















not	 RCT	 (8),	 pk	 outcome	 data	 only	 (6),	 duplicate	 (3),	 conference	 abstract	 (1),	 case	 report	 (1),	
preliminary	 data	 of	 an	 included	 published	 study	 (1),	 part	 not	 randomised	 (1),	 crossover	 (1),	
uncontrolled	(1),	not	clear	 if	 randomised	(1),	dosing	simulation	(1),	48	hours	then	all	 received	same	
therapy	(1),	study	protocol	(1).	
4.4.2	 Assessment	of	risk	of	bias	in	the	included	studies	
On	 the	 whole	 the	 articles	 generally	 showed	 a	 high	 or	 unclear	 risk	 of	 bias.	 This	 was	 particularly	
apparent	with	performance	bias,	as	only	three	studies	out	of	 the	40	assessed	were	double	blinded.	
Attrition	and	reporting	bias	faired	much	better	 in	general	with	62%	and	45%	of	articles	respectively	
being	 assessed	 as	 low	 risk.	No	 article	was	 low	 risk	 for	 all	methodological	 quality	markers	 assessed	
although	one	study	was	judged	to	be	at	low	risk	for	all	fields	except	for	an	unclear	risk	in	“other	bias”	
due	to	pharmaceutical	industry	sponsorship	(Dulhunty	et	al.,	2015).	For	an	overview	of	the	risk	of	bias	






















































































































































































































Abdul-Aziz	2016	 +	 +	 -	 -	 +	 +	 +	
Adembri	2008	 ?	 ?	 -	 -	 +	 +	 ?	
Angus	2000	 ?	 ?	 ?	 ?	 -	 -	 -	
Bao	2017	 ?	 ?	 -	 -	 ?	 +	 +	
Bodey	1979	 +	 ?	 ?	 ?	 -	 -	 ?	
Buck	2005	 ?	 ?	 -	 -	 +	 ?	 ?	
Chytra	2012	 ?	 +	 -	 -	 +	 +	 +	
Contrina-Luque	2015	 +	 ?	 ?	 ?	 ?	 ?	 ?	
De	Jongh	2007	 ?	 ?	 -	 -	 -	 ?	 ?	
Dulhunty	2013	 +	 ?	 +	 +	 +	 +	 ?	
Dulhunty	2015	 +	 +	 +	 +	 +	 +	 ?	
Fan	2017	 +	 -	 -	 -	 +	 ?	 ?	
Feld	1977	 ?	 ?	 ?	 ?	 -	 +	 ?	
Feld	1984	 ?	 ?	 ?	 ?	 +	 ?	 ?	
Georges	2005	 ?	 ?	 -	 -	 ?	 -	 ?	
Hanes	2000	 ?	 ?	 ?	 ?	 ?	 -	 ?	
Lagast	1983	 ?	 ?	 ?	 ?	 +	 -	 ?	
Laterre	2015	 ?	 ?	 ?	 ?	 ?	 -	 ?	
Lau	2006	 ?	 ?	 -	 -	 -	 -	 -	
Lipman	1999	 +	 ?	 ?	 ?	 ?	 ?	 -	
Lu	2013	 ?	 ?	 -	 -	 +	 ?	 ?	
Lubasch	2003	 ?	 ?	 -	 -	 +	 +	 ?	
McNabb	2001	 ?	 ?	 -	 -	 -	 +	 ?	
Nicolau	1999a	 ?	 ?	 ?	 ?	 +	 -	 ?	
Nicolau	1999b	 ?	 ?	 -	 -	 -	 -	 ?	
Nicolau	2001	 ?	 ?	 -	 -	 -	 +	 ?	
Okimoto	2009	 ?	 ?	 -	 -	 ?	 ?	 ?	
Rafati	2006	 ?	 ?	 ?	 ?	 +	 +	 ?	
Ram	2018	 +	 +	 -	 +	 +	 +	 ?	
Roberts	2007	 +	 +	 -	 +	 +	 +	 -	
Roberts	2009a	 ?	 +	 ?	 ?	 +	 ?	 ?	
Roberts	2009b	 ?	 +	 -	 -	 +	 +	 -	
Roberts	2010	 ?	 +	 -	 -	 +	 ?	 -	
Sakka	2007	 ?	 ?	 -	 -	 +	 ?	 ?	
Schmelzer	2013	 +	 ?	 -	 -	 ?	 ?	 -	
Van	Zanten	2006	 ?	 ?	 -	 -	 -	 ?	 ?	
Wright	1979	 ?	 ?	 -	 -	 ?	 ?	 ?	
Wysocki	2001	 +	 +	 -	 ?	 -	 -	 -	
Yang	2017	 ?	 ?	 -	 ?	 +	 +	 +	








Eleven	 articles	 (Bodey	 et	 al.,	 1979;	 Lipman	 et	 al.,	 1999;	Wysocki	 et	 al.,	 2001;	 Roberts	 et	 al.,	 2007;	
Dulhunty	 et	 al.,	 2013a,	 2015;	 Schmelzer	 et	 al.,	 2013;	 Abdul-Aziz	 et	 al.,	 2016;	 Cotrina-Luque	 et	 al.,	
2016;	 Fan	 et	 al.,	 2017;	 Ram	 et	 al.,	 2018)	 adequately	 described	 the	 generation	 of	 randomisation	
sequences	to	be	deemed	at	low	risk	of	bias.	The	remaining	29	articles	were	judged	to	have	an	unclear	
risk	of	bias	as	although	they	all	stated	that	the	patients	were	randomised	they	did	not	describe	the	
method	 of	 random	 sequence	 generation	 or	 the	 information	 was	 not	 available	 in	 the	 English	
translations	of	the	abstracts	(Okimoto	et	al.,	2009;	Lü	et	al.,	2013).	
4.4.2.2	 Selection	bias	-	Allocation	concealment	
Ten	 articles	 (Wysocki	 et	 al.,	 2001;	 Roberts	 et	 al.,	 2007,	 2009a,	 2009b,	 2010;	 Chytra	 et	 al.,	 2012;	
Dulhunty	 et	 al.,	 2015;	 Abdul-Aziz	 et	 al.,	 2016;	 Zhao	 et	 al.,	 2017;	 Ram	 et	 al.,	 2018)	 stated	 that	
randomisation	occurred	using	 sealed	opaque	envelopes	and	so	were	deemed	 to	be	 low	 risk.	 Seven	
articles	(Bodey	et	al.,	1979;	Feld	et	al.,	1984;	Buck	et	al.,	2005;	Sakka	et	al.,	2007;	Adembri	et	al.,	2008;	
Dulhunty	et	al.,	2013a;	Bao	et	al.,	2017)	stated	that	randomisation	occurred	using	sealed	envelopes	
but	 opacity	 was	 not	 stated	 so	 were	 deemed	 to	 be	 of	 unclear	 risk.	 One	 article	 (Fan	 et	 al.,	 2017)	
randomised	patients	by	hospital	number	 therefore	 the	enrolling	physician	would	be	able	 to	predict	
which	treatment	arm	the	patient	would	enter	so	was	deemed	to	be	high	risk.	Allocation	concealment	
was	 unclear	 in	 one	 article	 (Cotrina-Luque	 et	 al.,	 2016)	were	 it	 was	 not	 stated	whether	 un-blinded	
pharmacy	staff	involved	in	supply	of	the	randomised	therapy	were	involved	in	the	clinical	care	of	the	
patients	 so	 was	 deemed	 to	 be	 of	 unclear	 risk.	 The	 remaining	 21	 articles	 were	 judged	 to	 have	 an	





et	 al.,	 2007;	Adembri	 et	 al.,	 2008;	De	 Jongh	et	 al.,	 2008;	Okimoto	et	 al.,	 2009;	 Chytra	 et	 al.,	 2012;	






































patients	 screened	or	enrolled	 in	 the	 study	and	 so	was	deemed	 to	have	an	unclear	 risk	of	bias.	The	
remaining	 sixteen	 articles	 had	 one	 or	more	 issues	 relating	 to	 data	 completeness	 such	 as	 excluded	
patients,	patients	 lost	 to	 follow	up,	additional	outcomes	 included	not	 stated	a	priori.	 These	articles	
were	deemed	to	be	at	unclear	or	high	risk	of	bias.	
4.4.2.6	 Reporting	bias	-	Selective	reporting	




et	 al.,	 2016)	 reported	 on	 all	 pre-stated	 outcomes	 but	 states	 in	 the	 article	 the	 outcomes	 changed	




a	priori	 and	were	deemed	 to	be	at	unclear	or	high	 risk	of	bias.	One	article	 (Schmelzer	et	al.,	2013)	
collected	 data	 on	 clinical	 outcome	 but	 did	 not	 report	 the	 results	 in	 the	 article	 so	 was	 deemed	 at	
unclear	 risk	 of	 bias.	 Selective	 reporting	 was	 un-evaluable	 and	 therefore	 deemed	 unclear	 in	 two	







sources	 of	 bias	were	 unclear	 in	 two	 articles	 (Okimoto	 et	 al.,	 2009;	 Lü	 et	 al.,	 2013)	 as	 only	 English	
abstracts	 were	 available	 and	 so	 these	 studies	 were	 deemed	 to	 have	 unclear	 risk	 of	 bias.	 The	
remaining	thirty-four	articles	contained	one	or	more	of	the	following	potential	sources	of	other	bias;	
conflicts	 of	 interest	 not	 stated	 or	 potentially	 influential;	 industry	 funding	 or	 supply	 of	 antibiotics;	



























these	 articles	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 All	 of	 these	 articles	 reported	 studies	







Analysis	 of	 the	 funnel	 plot	 showing	 observed	 (white)	 and	 imputed	 (black)	 articles	 suggests	 that	
publication	bias	exists	favouring	articles	showing	a	positive	effect	from	extended	infusions.		
Study name Outcome Events / Total MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Abdul-Aziz 2016Clinical cure 24 / 70 39 / 70 10.37 1.625 1.105 2.390
Adembri 2008 Clinical cure 6 / 8 6 / 8 5.07 1.000 0.568 1.761
Chytra 2012 Clinical cure 24 / 120 30 / 120 7.10 1.250 0.779 2.007
Dulhunty 2013 Clinical cure 15 / 30 23 / 30 9.33 1.533 1.019 2.307
Dulhunty 2015 Clinical cure 109 / 220 111 / 212 34.55 1.057 0.878 1.272
Georges 2005 Clinical cure 16 / 24 22 / 26 13.94 1.269 0.915 1.760
Laterre 2015 Clinical cure 11 / 14 13 / 14 15.32 1.182 0.867 1.611
Nicolau 2001 Clinical cure 6 / 18 7 / 17 2.22 1.235 0.520 2.936
Roberts 2007 Clinical cure 5 / 28 13 / 29 2.10 2.510 1.030 6.120
1.231 1.081 1.403
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Figure	 4.2:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	95%	 confidence	 interval	 (95%	CI)	 of	 serious	 adverse	 events	
(SAE)	of	patients	receiving	“Extended”	(extended	intermittent	or	continuous	 infusions	(EI))	versus	“Intermittent”	(bolus	or	
short	infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	














MH log risk ratio
Funnel Plot of Standard Error by MH log risk ratio
Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Dulhunty 2015 SAE 25 / 220 19 / 212 81.61 0.789 0.448 1.389
Bao 2017 SAE 4 / 25 5 / 25 18.39 1.250 0.379 4.118
0.858 0.515 1.431
0.01 0.1 1 10 100












Figure	 4.3a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	 clinical	 response	 of	
patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test.	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
publication	 bias	 exists	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	 extended	
infusions.	Trim	and	Fill	(Duval	and	Tweedie,	2000)	identifies	2	potentially	missing	studies	but	doesn’t	
alter	 the	 statistical	 significance	 of	 the	 result	 (random	 effects	model,	 point	 estimate	 1.007,	 95%	 CI	
0.958	to	1.058).	
Study name Outcome Events / Total MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Buck 2005 Clinical response 8 / 12 8 / 12 0.88 1.000 0.568 1.761
Chytra 2012 Clinical response 81 / 120 88 / 120 10.41 1.086 0.922 1.281
Hanes 2000 Clinical response 10 / 14 9 / 16 0.95 0.788 0.457 1.357
Lau 2006 Clinical response 104 / 130 96 / 128 16.19 0.938 0.822 1.070
Lubasch 2003 Clinical response 36 / 40 37 / 41 13.54 1.003 0.868 1.158
Nicolau 2001 Clinical response 15 / 18 16 / 17 4.96 1.129 0.890 1.433
Roberts 2007 Clinical response 23 / 28 25 / 29 5.52 1.049 0.837 1.315
van Zanten 2006 Clinical response 40 / 43 37 / 40 19.44 0.994 0.882 1.122
Wysocki 2001 Clinical response a 47 / 58 48 / 61 8.65 0.971 0.811 1.163
Bao 2017 Clinical response 20 / 25 22 / 25 4.74 1.100 0.862 1.403
Ram 2018 Clinical response 47 / 58 44 / 47 13.36 1.155 0.999 1.336
Zhao 2017 Clinical response 14 / 25 16 / 25 1.36 1.143 0.725 1.802
1.027 0.974 1.083
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visually	 in	 the	 forest	plot.	Nineteen	of	 these	articles	 reported	 studies	 investigating	 time-dependent	
antibiotics,	3	(Feld	et	al.,	1977,	1984;	Wright	et	al.,	1979)	concentration	dependent	and	one	MIC:AUC	
ratio	(Wysocki	et	al.,	2001).	No	statistically	significant	difference	in	mortality	was	observed	(n	=	2165,	
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Figure	 4.4a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	mortality	 of	 patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	 the	 funnel	plot	 showing	both	observed	 (white)	and	 imputed	studies	 suggests	 that	 there	
are	no	missing	studies	and	that	no	publication	bias	exists.		
	
Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Abdul-Aziz 2016 Mortality 26 / 70 18 / 70 9.63 0.692 0.419 1.143
Angus 2000 Mortality 9 / 11 3 / 10 2.49 0.367 0.137 0.984
Chytra 2012 Mortality 28 / 120 21 / 120 9.45 0.750 0.452 1.244
Cotrina-Luque 2016 Mortality 1 / 38 0 / 40 0.24 0.317 0.013 7.552
Dulhunty 2013 Mortality 6 / 30 3 / 30 1.45 0.500 0.138 1.817
Dulhunty 2015 Mortality 62 / 220 56 / 212 25.49 0.937 0.689 1.276
Feld 1977 Mortality c 6 / 57 8 / 63 2.44 1.206 0.446 3.266
Feld 1984 Mortality c 5 / 16 2 / 10 1.17 0.640 0.152 2.693
Georges 2005 Mortality 3 / 24 3 / 26 1.07 0.923 0.206 4.141
Hanes 2000 Mortality 4 / 25 5 / 20 1.75 1.563 0.482 5.065
Laterre 2015 Mortality 5 / 14 2 / 14 1.13 0.400 0.093 1.727
Rafati 2006 Mortality 6 / 20 5 / 20 2.36 0.833 0.303 2.293
Roberts 2007 Mortality 0 / 28 3 / 29 0.28 6.767 0.365 125.325
Roberts 2009a Mortality 0 / 5 2 / 5 0.30 5.000 0.299 83.685
Sakka 2007 Mortality 2 / 10 1 / 10 0.48 0.500 0.054 4.672
van Zanten 2006 Mortality 1 / 46 4 / 47 0.52 3.915 0.455 33.719
Wright 1979 Mortality c 3 / 13 5 / 23 1.53 0.942 0.267 3.319
Wysocki 2001 Mortality a 19 / 58 21 / 61 9.46 1.051 0.634 1.743
Fan 2017 Mortality 59 / 185 52 / 182 24.93 0.896 0.656 1.223
Ram 2018 Mortality 2 / 58 1 / 47 0.43 0.617 0.058 6.597
Zhao 2017 Mortality 8 / 25 7 / 25 3.36 0.875 0.374 2.046
0.868 0.743 1.014
0.01 0.1 1 10 100




Nineteen	 articles	 compared	 time-dependent	 antibiotics	 (Angus	 et	 al.,	 2000;	 Hanes	 et	 al.,	 2000;	




assessed	 and	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 A	 statistically	 significant	 difference	 in	
mortality	 was	 observed	 (n	 =	 1861,	 RR	 0.844,	 95%	 CI	 0.713	 to	 0.999,	 p	 =	 0.049).	 No	 evidence	 of	
statistical	heterogeneity	was	found	(df	=	16,	P	=	0.676,	I2	=	0.0%).	
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Figure	 4.5a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	mortality	 of	 patients	
receiving	“Extended”	(extended	intermittent	or	continuous	infusions	(EI))	versus	“Intermittent”	(bolus	or	short	infusions	(II))	
of	various	time-dependent	antibiotics.	MH	=	Mantel-Haenszel	test	






Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Abdul-Aziz 2016 Mortality 26 / 70 18 / 70 11.28 0.692 0.419 1.143
Angus 2000 Mortality 9 / 11 3 / 10 2.91 0.367 0.137 0.984
Chytra 2012 Mortality 28 / 120 21 / 120 11.07 0.750 0.452 1.244
Cotrina-Luque 2016 Mortality 1 / 38 0 / 40 0.28 0.317 0.013 7.552
Dulhunty 2013 Mortality 6 / 30 3 / 30 1.70 0.500 0.138 1.817
Dulhunty 2015 Mortality 62 / 220 56 / 212 29.85 0.937 0.689 1.276
Georges 2005 Mortality 3 / 24 3 / 26 1.26 0.923 0.206 4.141
Hanes 2000 Mortality 4 / 25 5 / 20 2.05 1.563 0.482 5.065
Laterre 2015 Mortality 5 / 14 2 / 14 1.32 0.400 0.093 1.727
Rafati 2006 Mortality 6 / 20 5 / 20 2.77 0.833 0.303 2.293
Roberts 2007 Mortality 0 / 28 3 / 29 0.33 6.767 0.365 125.325
Roberts 2009b Mortality 0 / 5 2 / 5 0.36 5.000 0.299 83.685
Sakka 2007 Mortality 2 / 10 1 / 10 0.57 0.500 0.054 4.672
van Zanten 2006 Mortality 1 / 46 4 / 47 0.61 3.915 0.455 33.719
Fan 2017 Mortality 59 / 185 52 / 182 29.20 0.896 0.656 1.223
Ram 2018 Mortality 2 / 58 1 / 47 0.51 0.617 0.058 6.597
Zhao 2017 Mortality 8 / 25 7 / 25 3.93 0.875 0.374 2.046
0.844 0.713 0.999
0.01 0.1 1 10 100
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Figure	4.6a:	Forest	plot	depicting	the	risk	ratio	and	associated	95%	confidence	 interval	 (95%	CI)	of	 infection	recurrence	of	
patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
some	 publication	 bias	 may	 exist	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	
extended	 infusions.	 Trim	and	 Fill	 (Duval	 and	Tweedie,	 2000)	 identifies	 2	potentially	missing	 studies	
which	 do	 not	 alter	 the	 statistical	 significance	 of	 the	 result	 (random	 effects	 model,	 point	 estimate	
0.500,	95%	CI	0.145	to	1.718).	
Study name Outcome Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit
Lu 2013 Recurrence 2 / 25 1 / 25 43.67 0.500 0.048 5.168
Roberts 2007 Recurrence 0 / 28 1 / 29 23.86 2.900 0.123 68.331
Lagast 1983 Recurrence 1 / 25 1 / 20 32.47 1.250 0.083 18.763
1.024 0.219 4.793
0.01 0.1 1 10 100








Figure	 4.7a:	 Forest	 plot	 depicting	 the	 risk	 ratio	 and	 associated	 95%	 confidence	 interval	 (95%	 CI)	 of	
microbiological/bacteriological	 cure	 of	 patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	
versus	“Intermittent”	(bolus	or	short	infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	
All	 of	 these	 articles	 reported	 studies	 investigating	 time-dependent	 antibiotics.	 A	 statistically	
significant	difference	in	microbiological	cure	was	observed	(n	=	403,	RR	1.177,	95%	CI	1.054	to	1.313,	
p	=	0.004).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	4,	P	=	0.936,	I2	=	0.0%).	
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Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit p-Value
Adembri 2008 Microbiological cure 7 / 11 8 / 9 4.77 1.397 0.845 2.310 0.193
Chytra 2012 Microbiological cure80 / 102 87 / 96 83.20 1.155 1.024 1.303 0.019
Cotrina-Luque 2016Microbiological cure 3 / 38 3 / 40 0.51 0.950 0.204 4.420 0.948
Georges 2005 Bacteriological cure 13 / 24 18 / 26 6.00 1.278 0.816 2.001 0.284
Roberts 2007 Bacteriological cure 14 / 28 18 / 29 5.53 1.241 0.778 1.980 0.364
1.177 1.054 1.313 0.004
0.1 0.2 0.5 1 2 5 10
Favours Intermittent Favours Extended
	 103	
Analysis	of	the	funnel	plot	showing	both	observed	(white)	and	imputed	(black)	studies	suggests	that	
some	 publication	 bias	 may	 exist	 favouring	 publication	 of	 articles	 showing	 a	 positive	 effect	 from	
extended	infusions.	Trim	and	Fill	(Duval	and	Tweedie,	2000)	only	identifies	1	potentially	missing	study	






2016;	 Zhao	 et	 al.,	 2017)	 reported	 secondary/super-infection	 with	 a	 presumed	 or	 proven	 different	
organism.	Eight	of	these	articles	reported	studies	investigating	time-dependent	antibiotics,	one	(Feld	
et	 al.,	 1984)	 investigated	 concentration-dependent.	 No	 statistically	 significant	 difference	 in	
secondary/super-infection	was	observed	 (n	=	596,	RR	1.120,	 95%	CI	 0.662	 to	1.896,	 P	 =	0.673).	No	
evidence	of	statistical	heterogeneity	was	found	(df	=	8,	P	=	0.548,	I2	=	0.0%).	
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Study name Outcome Statistics for each study MH risk ratio and 95% CI
Relative MH risk Lower Upper 
II EI weight ratio limit limit p-Value
Chytra 2012 Superinfection 8 / 102 7 / 96 29.13 0.930 0.351 2.466 0.884
Cotrina-Luque 2016Superinfection 0 / 38 4 / 40 3.32 8.561 0.476 153.835 0.145
Feld 1984 Superinfection c 1 / 40 2 / 30 5.00 2.667 0.253 28.054 0.414
Georges 2005 Superinfection 4 / 24 3 / 26 14.34 0.692 0.172 2.780 0.604
Hanes 2000 Superinfection 3 / 14 7 / 16 21.08 2.042 0.649 6.426 0.222
Laterre 2015 Superinfection 0 / 14 1 / 14 2.85 3.000 0.133 67.910 0.490
McNabb 2001 Superinfection 3 / 18 3 / 17 13.06 1.059 0.247 4.544 0.939
Roberts 2007 Superinfection 2 / 28 1 / 29 5.05 0.483 0.046 5.030 0.543
Zhao 2017 Superinfection 4 / 25 1 / 25 6.17 0.250 0.030 2.083 0.200
1.120 0.662 1.896 0.673
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all	 patients	 assessed	 and	 are	 not	 represented	 visually	 in	 the	 forest	 plot.	 Eleven	 of	 these	 articles	





Study name Outcome Events / Total Statistics for each study MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Lau 2006 Withdrawal due to AE 1 / 132 2 / 130 33.66 2.031 0.186 22.123
Bao 2017 Withdrawal due to AE 3 / 25 2 / 25 66.34 0.667 0.122 3.653
0.970 0.243 3.877
0.01 0.1 1 10 100






patients	 receiving	 “Extended”	 (extended	 intermittent	 or	 continuous	 infusions	 (EI))	 versus	 “Intermittent”	 (bolus	 or	 short	
infusions	(II))	of	various	antibiotics.	MH	=	Mantel-Haenszel	test	






Study name Outcome Events / Total MH risk ratio and 95% CI
Intermittent Extended Relative MH risk Lower Upper 
infusion infusion weight ratio limit limit
Dulhunty 2015 AE 28 / 220 20 / 212 16.42 0.741 0.431 1.274
Feld 1984 AE c 6 / 40 2 / 28 2.57 0.476 0.104 2.190
Laterre 2015 AE 0 / 14 1 / 14 0.63 3.000 0.133 67.910
Lau 2006 AE 18 / 132 22 / 130 15.00 1.241 0.699 2.203
McNabb 2001 AE 13 / 18 11 / 17 21.45 0.896 0.569 1.410
Schmelzer 2013 AE a 3 / 27 1 / 28 1.26 0.321 0.036 2.903
Bao 2017 AE 19 / 25 23 / 25 42.67 1.211 0.944 1.552
1.015 0.791 1.302
0.01 0.1 1 10 100
Favours Extended Favours Intermittent













MH log risk ratio










Adverse	 events	 (AE):	 Five	 articles	 (Lau	 et	 al.,	 2006;	Dulhunty	 et	 al.,	 2013a,	 2015;	Abdul-Aziz	 et	 al.,	
2016;	 Fan	 et	 al.,	 2017)	 reported	 AE.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	more	
than	 one	 antibiotic	 and	 separate	 data	 for	 piperacillin/tazobactam	 was	 unavailable.	 Two	 articles	




Cotrina-Luque	 et	 al.,	 2016)	 reported	 clinical	 cure.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	
investigated	 more	 than	 one	 antibiotic	 and	 although	 published	 data	 for	 piperacillin/tazobactam	 is	
unavailable	the	authors	were	able	to	provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	

















(Roberts	 et	 al.,	 2010)	 reported	no	deaths	 in	 either	 group.	No	 statistically	 significant	difference	was	
observed	 (n	 =	 824,	 RR	 0.904,	 95%	 CI	 0.716	 to	 1.141,	 p	 =	 0.396).	 No	 evidence	 of	 statistical	
heterogeneity	was	found	(df	=	4,	P	=	0.763,	I2	=	0.0%)	
Microbiological/bacteriological	 cure:	 One	 article	 (Cotrina-Luque	 et	 al.,	 2016)	 reported	
microbiological	cure	and	found	no	statistically	significant	difference	(n	=	78,	RR	0.950,	95%	CI	0.204	to	
4.420,	 p	 =	 0.948).	 The	 number	 of	 articles	 reporting	 microbiological/bacteriological	 cure	 was	
insufficient	to	assess	for	statistical	heterogeneity.	
Super-infection:	 One	 article	 (Cotrina-Luque	 et	 al.,	 2016)	 reported	 super-infection	 and	 found	 no	
statistically	significant	difference	(n	=	78,	RR	8.561,	95%	CI	0.476	to	153.835,	p	=	0.145).	The	number	
of	articles	reporting	super-infection	was	insufficient	to	assess	for	statistical	heterogeneity.	









articles;	 AE,	 clinical	 cure,	 clinical	 response,	 mortality,	 microbiological/bacteriological	 cure,	 super-
infection	and	WAE.	
Adverse	events	(AE):	Four	articles	(Chytra	et	al.,	2012;	Dulhunty	et	al.,	2013a,	2015;	Abdul-Aziz	et	al.,	
2016)	 investigated	 AE.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	 more	 than	 one	





reported	 clinical	 cure.	 Two	 articles	 (Dulhunty	 et	 al.,	 2013a,	 2015)	 investigated	 more	 than	 one	




Clinical	 response:	 Three	 articles	 (Dulhunty	 et	 al.,	 2013a;	 Abdul-Aziz	 et	 al.,	 2016;	 Zhao	 et	 al.,	 2017)	
reported	clinical	response.	One	article	(Dulhunty	et	al.,	2013a)	investigated	more	than	one	antibiotic	
and	 separate	 data	 for	meropenem	was	 unavailable.	 No	 statistically	 significant	 difference	 in	 clinical	
response	 was	 observed	 (n	 =	 290,	 RR	 1.093,	 95%	 CI	 0.936	 to	 1.276,	 p	 =	 0.261).	 No	 evidence	 of	
statistical	heterogeneity	was	found	(df	=	1,	P	=	0.837,	I2	=	0.0%)	
All-cause	mortality:	 Five	 articles	 (Roberts	 et	 al.,	 2009a;	Chytra	et	 al.,	 2012;	Dulhunty	et	 al.,	 2013a,	
2015;	Zhao	et	al.,	2017)	reported	mortality.	Two	articles	 (Dulhunty	et	al.,	2013a,	2015)	 investigated	
more	 than	 one	 antibiotic	 and	 although	 published	 data	 for	 meropenem	 is	 unavailable	 the	 authors	
were	able	to	provide	a	breakdown	by	antibiotic	for	the	published	outcomes.	One	article	(Dulhunty	et	
al.,	2013a)	reported	no	deaths	in	either	group.	No	statistically	significant	difference	in	mortality	was	





95%	CI	 0.936	 to	 1.408,	 p	 =	 0.184).	 The	 number	 of	 articles	 reporting	microbiological/bacteriological	
cure	was	insufficient	to	assess	for	statistical	heterogeneity.	
Super-infection:	Two	articles	(Chytra	et	al.,	2012;	Zhao	et	al.,	2017)	reported	super-infection	and	no	
significant	 statistical	 difference	 between	 treatment	 groups	was	 observed	 (n	 248,	 RR	 0.682,	 95%	 CI	
0.227	to	2.049,	p	=	0.495).	No	evidence	of	statistical	heterogeneity	was	found	(df	=	1,	P	=	0.267,	I2	=	
18.9%)	



















patients	 received	 ceftazidime,	 a	 breakdown	 of	 results	 by	 antibiotic	 was	 unavailable	 at	 the	 time	 of	
thesis	 write	 up	 and	 so	 this	 study	 could	 not	 be	 further	 analysed.	 The	 following	 outcomes	 were	






rather	 than	 by	 treatment	 arm	 however	 the	 events	 from	Nicolau	 et	 al.	 2001	 are	 reported	 in	 full	 in	
McNabb	 et	 al.	 2001.	 One	 article	 (Nicolau	 et	 al.,	 1999b)	 reported	 no	 adverse	 events	 in	 either	
treatment	 arm.	No	 statistically	 significant	 difference	 in	AE	was	observed	 (n	 =	 59,	 RR	0.896,	 95%	CI	
0.569	to	1.410,	p	=	0.635).	The	number	of	articles	reporting	AE	was	insufficient	to	assess	for	statistical	
heterogeneity.	
Clinical	 cure:	One	 article	 (Nicolau	 et	 al.,	 2001)	 reported	 clinical	 cure	 and	 no	 statistically	 significant	
difference	 between	 treatment	 groups	was	 observed	 (n	 =	 35,	 RR	 1.235,	 95%	CI	 0.520	 to	 2.936,	 p	 =	
0.632).	 The	 number	 of	 articles	 reporting	 clinical	 cure	 was	 insufficient	 to	 assess	 for	 statistical	
heterogeneity.	
Clinical	 response:	 Three	 articles	 (Hanes	 et	 al.,	 2000;	 Nicolau	 et	 al.,	 2001;	 Lubasch	 et	 al.,	 2003)	
reported	clinical	response.	No	statistically	significant	difference	in	clinical	response	was	observed	(n	=	










super-infection.	One	 article	 (Nicolau	 et	 al.,	 2001)	was	 not	 analysed	 further	 as	 it	 did	 not	 report	 the	
actual	 number	 of	 events	 in	 each	 treatment	 arm,	 results	 from	 this	 study	 for	 super-infection	 were	
available	in	the	article	by	McNabb	et	al..	No	statistically	significant	difference	in	super-infection	rate	

























Clinical	cure	 	 	 	 	 	 	 	 	 	 	
	









	 P/T	 424	 1.395	 1.035	 1.882	 0.029	 2	 31.9	 	 	 	
	 M	 428	 1.214	 0.860	 1.714	 0.271	 3	 57.3	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 35	 1.235	 0.520	 2.936	 0.632	 NA	 NA	 	 	 	
Clinical	response	 	 	 	 	 	 	 	 	 	 	
	









	 P/T	 332	 0.973	 0.869	 1.090	 0.639	 2	 0.0	 	 	 	
	 M	 290	 1.093	 0.936	 1.276	 0.261	 1	 0.0	 	 	 	
	 V	 119	 0.971	 0.811	 1.163	 0.750	 NA	 NA	 	 	 	
	 C	 146	 1.021	 0.906	 1.152	 0.729	 2	 0.0	 	 	 	
All	cause	mortality	 	 	 	 	 	 	 	 	 	 	
	









	 P/T	 824	 0.904	 0.716	 1.141	 0.396	 4	 0.0	 	 	 	
	 M	 445	 0.816	 0.586	 1.136	 0.229	 3	 0.0	 	 	 	
	 V	 119	 1.051	 0.634	 1.743	 0.847	 NA	 NA	 	 	 	
	 C	 21	 0.367	 0.137	 0.984	 0.046	 NA	 NA	 	 	 	
AE	 	 	 	 	 	 	 	 	 	 	 	
	









	 P/T	 716	 1.241	 0.699	 2.203	 0.461	 NA	 NA	 	 	 	
	 M	 380	 0.833	 0.374	 1.855	 0.655	 NA	 NA	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 59	 0.896	 0.569	 1.410	 0.635	 NA	 NA	 	 	 	
SAE	 	 	 	 	 	 	 	 	 	 	 	
	 All	 482	 0.858	 0.515	 1.431	 0.558	 1	 0.0	 NA	 NA	 NA	
	 Time	
only	 482	 0.858	 0.515	 1.431	 0.558	 1	 0.0	 NA	 NA	 NA	
	 P/T	 	 	 	 	 	 	 	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
WAE	 	 	 	 	 	 	 	 	 	 	 	
	 All	 597	 0.970	 0.243	 3.877	 0.966	 1	 0.0	 NA	 NA	 NA	
	 Time	
only	 597	 0.970	 0.243	 3.877	 0.966	 1	 0.0	 NA	 NA	 NA	
	 P/T	 262	 2.031	 0.186	 22.123	 0.561	 NA	 NA	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	



























Infection	recurrence	 	 	 	 	 	 	 	 	 	








	 P/T	 	 	 	 	 	 	 	 	 	 	
	 M	 	 	 	 	 	 	 	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
Microbiological/bacteriological	cure	 	 	 	 	 	 	 	
	









	 P/T	 78	 0.950	 0.204	 4.420	 0.948	 NA	 NA	 	 	 	
	 M	 198	 1.148	 0.936	 1.408	 0.184	 NA	 NA	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	
	 C	 	 	 	 	 	 	 	 	 	 	
Super-infection	 	 	 	 	 	 	 	 	 	 	
	 All	









	 P/T	 78	 8.561	 0.476	 153.835	 0.145	 NA	 NA	 	 	 	
	 M	 248	 0.682	 0.227	 2.049	 0.495	 1	 18.9	 	 	 	
	 V	 	 	 	 	 	 	 	 	 	 	




The	 removal	 of	 individual	 studies	 had	 no	 effect	 on	 the	 statistical	 significance	 of	 the	 primary	
outcomes.	 Clinical	 cure	 still	 favours	 CI	 (RR	 range	 1.192	 –	 1.335	 with	 associated	 p-value	 range	 of	
<0.001	 to	0.012)	 and	 SAE	 shows	no	difference	between	administration	methods	 (RR	 range	0.789	–	
1.250	with	associated	p-value	range	of	0.411	to	0.714).		
Mortality	remains	not	statistically	significant	(RR	range	0.846	–	0.889	with	associated	p-value	range	of	
0.053	 to	 0.160).	 Analysis	 of	 mortality	 in	 articles	 investigating	 only	 time-dependent	 antibiotics	 had	
previously	 shown	 a	 difference	 between	 administration	 methods	 favouring	 CIs,	 re-analysis	 with	
individual	 studies	 removed	 renders	 a	 neutral	 result	 favouring	 neither	 method	 in	 11	 out	 of	 17	
instances	(RR	range	0.808	–	0.866	with	associated	p-value	range	of	0.036	to	0.114).	In	addition	to	the	
17	articles	analysed,	 two	articles	 (De	Jongh	et	al.,	2008;	Roberts	et	al.,	2010)	reported	no	deaths	 in	







(RR	 1.236,	 95%	 CI	 1.088	 to	 1.403,	 p-value	 0.001)	 and	 SAE	 still	 shows	 no	 difference	 between	
administration	methods	(RR	0.853,	95%	CI	0.513	to	1.421,	p-value	0.542)	
Mortality	remains	neutral	(RR	0.879,	95%	CI	0.753	to	1.026,	p-value	0.102).	However,	using	the	fixed	
effects	 model	 on	 mortality	 associated	 with	 time-dependent	 antibiotics	 renders	 the	 previously	
statistically	 significant	 result	 neutral	 suggesting	no	difference	between	 administration	methods	 (RR	






to	 2.329,	 p-value	 0.002)	 and	 SAE	 still	 shows	 no	 difference	 between	 administration	 methods	 (OR	
0.836,	95%	CI	0.469	to	1.488,	p-value	0.542)	
Mortality	remains	neutral	(OR	0.832,	95%	CI	0.672	to	1.030,	p-value	0.091).	However,	using	odd	ratio	
to	 analyse	mortality	 associated	with	 time-dependent	 antibiotics	 renders	 the	 previously	 statistically	
significant	 result	 neutral,	 favouring	 neither	 method	 of	 administration	 (OR	 0.802,	 95%	 CI	 0.637	 to	
1.010,	 P	 =	 0.061).	Microbiological/bacteriological	 cure	 still	 favours	 CIs	 (OR	 2.036,	 95%	 CI	 1.204	 to	
3.444,	p-value	0.008).	
4.4.4.4		 Analysing	only	articles	looking	at	continuous	infusions	
Analysis	 of	 articles	 just	 reporting	 studies	 investigating	 continuous	 infusions,	 i.e.	 excluding	 those	
looking	 at	 extended	 intermittent	 infusions,	 did	 not	 affect	 the	 statistical	 significance	 of	 the	 primary	
outcomes;	 clinical	 cure	 still	 favours	extended	 infusions	 (RR	1.231,	95%	CI	1.081	 to	1.403,	p-value	=	
0.002)	and	SAE	remained	neutral	(RR	0.789,	95%	CI	0.448	to	1.389,	p-value	=	0.411).		
Mortality	 remained	 neutral	 (RR	 0.861,	 95%	 CI	 0.719	 to	 1.031,	 p-value	 =	 0.103),	 the	 statistical	
significance	of	mortality	associated	with	 just	 time-dependent	antibiotics	however	was	affected;	 this	
result	no	 longer	favoured	either	administration	method	(RR	0.826,	95%	CI	0.675	to	1.009,	p-value	=	








was	 decided	 a	 priori	 to	 exclude	 vancomycin	 from	 “time	 only”	 analysis	 as	 a	 major	 part	 of	 the	
justification	for	extended	infusions	is	to	increase	the	T>MIC.	






A	 statistical	 significant	 difference	 in	 both	 clinical	 cure	 and	microbiological/bacteriological	 cure	was	
observed	between	extended	and	 intermittent	 infusions	of	 antibiotics	 favouring	 extended	 infusions.	
No	 difference	 in	 all-cause	 mortality,	 clinical	 response,	 super-infection	 or	 infection	 recurrence	 was	
observed	 between	 administration	 methods.	 Nor	 was	 any	 difference	 in	 adverse	 events,	 serious	
adverse	events	or	withdrawal	due	to	adverse	events	found	between	administration	methods.	Analysis	
of	only	antibiotics	exhibiting	 time-dependent	action	observed	a	 statistically	 significant	difference	 in	
all-cause	 mortality,	 clinical	 cure	 and	 microbiological/bacteriological	 cure	 between	 extended	 and	
intermittent	 infusions	 favouring	 extended	 infusions.	 Analysis	 of	 all	 other	 primary	 and	 secondary	
outcomes	 found	 no	 difference	 between	 administration	methods.	 Sub-group	 analysis	 of	 all	 primary	
and	 secondary	 outcomes	 for	 individual	 antibiotics	 observed	 a	 statistically	 significant	 difference	
between	administration	methods	associated	with	piperacillin	 (+/-	 tazobactam)	and	clinical	 cure	and	
ceftazidime	and	all-cause	mortality	again	favouring	extended	infusions.	No	differences	were	found	for	
all	 other	 outcomes	 and	 the	 individual	 antibiotics	 investigated.	 Sensitivity	 analysis	 supported	 the	








As	 shown	 by	 this	 systematic	 review,	 interest	 in	 the	 potential	 benefits	 of	 extended	 infusions	 of	
antibiotics	is	wide	reaching	and	the	subject	has	been	intensively	investigate	for	at	least	the	last	four	
decades.	Since	2003,	on	average,	2	RCTs	have	been	published	each	year	with	12	published	in	the	last	
5	 years.	 Many	 different	 benefits	 have	 been	 postulated	 predominately	 focusing	 on	 two	 general	
themes,	efficacy	and	safety.	Investigators	have	also	looked	into	other,	non-clinical,	outcomes	such	as	
length	of	 stay,	 reducing	 the	 total	 amount	of	 antibiotic	used	or	 cost	 savings.	Reducing	antimicrobial	
resistance	is	a	newer	emerging	theme.		




increase	 the	 spectrum	 of	 activity.	 A	 number	 of	 more	 recent	 studies	 investigated	 more	 than	 one	
antibiotic	 under	 the	umbrella	of	 “β-lactams”	 (Dulhunty	et	 al.,	 2013a,	 2015;	Abdul-Aziz	 et	 al.,	 2016)	
allowing	individual	sites	in	multi-centred	international	studies	to	use	antibiotics	in	line	with	their	local	
antimicrobial	guidelines.	Although	there	was	a	great	number	of	antibiotics	investigated	the	majority,	
thirty-three,	of	 the	articles	 focused	solely	on	β-lactams.	This	 is	both	 logical	and	evidenced	based	as	
not	 only	 do	 β-lactams	 exhibit	 time-dependent	 action	 but	 the	 main	 pk/pd	 parameter	 aligned	 with	
efficacy	 is	T>MIC	 (Ambrose	et	al.,	2007).	Of	 the	remaining	7	articles	4	 investigated	aminoglycosides	
(Feld	 et	 al.,	 1977,	 1984;	 Bodey	 et	 al.,	 1979;	 Wright	 et	 al.,	 1979).	 Although	 this	 would	 now	 seem	
illogical,	at	the	time	in	the	mid	to	late	1970s,	the	influence	of	the	pk/pd	relationship	on	the	efficacy	of	
antibiotics	was	poorly	appreciated.	Harry	Eagle	had	postulated	that	continuous	infusions	of	penicillins	
would	 be	 beneficial	 in	 the	 1950s	 (Eagle	 et	 al.,	 1953)	 but	 it	 wasn’t	 really	 until	 the	 1990s	 that	 the	
different	groups	of	antibiotics	and	their	pk/pd	parameters	was	being	fully	understood	(Craig,	1998).		
Aside	 from	 the	 antibiotic	 being	 investigated	 most	 studies	 either	 did	 not	 discuss	 or	 allowed	




the	 need	 to	 prescribe	 non-study	 antibiotics	 as	 clinical	 failure	 (Bao	 et	 al.,	 2017).	 	 Substantial	
differences	in	the	approach	to	concomitant	antibiotic	use	make	interpretation	of	the	overall	result	of	
the	 meta-analysis	 complex.	 In	 many	 cases	 a	 microorganism	 isn’t	 cultured	 and	 so	 it	 would	 be	
impossible	 to	 state	 categorically	 which	 antibiotic	 had	 been	 effective	 and	 therefore	 which	 infusion	
method	is	superior.	
Another	 source	 of	 variation	 throughout	 the	 articles	 is	 the	 patient	 group	 selected.	 Although	 the	




also	 varied,	 frequently	 it	 focused	on	 “critically	 ill”	 patients	 regardless	of	 premorbid	 state	but	 some	
articles	looked	at	specific	patient	groups,	for	example	with	malignancies	+/-	neutropenia	(Bodey	et	al.,	
1979),	 trauma	 (Hanes	 et	 al.,	 2000)	 or	 chronic	 co-morbidities	 such	 as	 pneumonia	 in	 the	 context	 of	
patients	with	chronic	obstructive	airways	disease	(van	Zanten	et	al.,	2007).	To	complicate	this	further,	






The	affect	 that	 the	 factors	described	above	will	 have	on	 the	 results	of	 the	meta-analysis	 is	hard	 to	
precisely	quantify	and	can	only	 really	be	highlighted	 so	 the	 reader	 can	make	 their	own	 judgement.	
However,	 due	 to	 the	 volume	of	RCTs	 in	 the	 literature	 future	 systematic	 reviews	 could	afford	 to	be	













have	 been	 powered	 for	 is	 also	 relatively	 new.	 Although	 the	 meta-analysis	 has	 been	 around	 in	













i.e.	blind	both	at	 the	point	of	care	and	at	 the	point	of	assessment,	 to	be	 judged	at	 low	risk	of	both	
performance	 and	 detection	 bias.	 After	 publishing	 the	 study	 protocol	 (Dulhunty	 et	 al.,	 2013b)	 the	
group	then	went	on	to	do	a	small	scale	RCT	in	part	aimed	at	validating	the	blinding	process	(Dulhunty	
et	 al.,	 2013a)	 before	 finally	 stepping	 up	 to	 an	 adequately	 powered	 study	 (Dulhunty	 et	 al.,	 2015).	










Of	 the	 remaining	areas	of	potential	bias	assessed	“attrition	bias”,	 the	 loss	of	patients	 to	 follow	up,	
was	globally	managed	well	with	over	50%	of	articles	clearly	accounting	for	any	patients	that	were	not	










results	 of	 the	 meta-analysis.	 As	 for	 funding	 and	 declarations,	 it	 would	 be	 unfair	 to	 say	 that	 just	
because	 a	 study	 or	 one	 of	 its	 authors	 has	 an	 association	 with	 the	 pharmaceutical	 industry	 it	 is	
therefore	 inherently	 biased	 and	 therefore	 at	 high	 risk.	 Large	 studies	 cost	 vast	 sums	 of	money	 and	
would	 not	 be	 possible	 without	 external	 funding	 sources,	 be	 that	 national	 charitable/research	







antibiotics.	 This	 difference	 was	 still	 present	 when	 only	 time-dependent	 action	 antibiotics	 were	
analysed	and	was	also	seen	in	subgroup	analysis	of	piperacillin/tazobactam	but	wasn’t	present	in	the	
other	individual	antibiotics	examined.	Sensitivity	analysis	carried	out	to	assess	the	influence	of	choice	
of	statistical	methods	appears	 to	support	 the	observed	difference;	 the	use	of	both	random	or	 fixed	
effects	models	and	odds	or	risk	ratio	favour	extended	infusions.		
This	appears	 to	be	the	 first	systematic	 review	to	separate	out	clinical	cure	from	clinical	 response	 (a	
combination	of	both	clinical	cure	and	clinical	 improvement).	Frequently	previous	systematic	reviews	
have	combined	papers	 reporting	cure	with	 those	 reporting	 response.	Other	 reviews	have	 looked	at	
clinical	failure	(usually	defined	as	the	opposite	of	clinical	response	i.e.	no	improvement,	worsening	or	
death).	 In	 keeping	 with	 previous	 reviews	 this	 meta-analysis	 has	 shown	 no	 difference	 in	 clinical	
response	rate.	
The	 different	 ways	 in	 which	 clinical	 success	 has	 been	 reported	 in	 the	 RCTs	 was	 not	 anticipated	 a	
priori.	The	decision	to	include	both	clinical	cure	and	clinical	response	as	separate	results	for	analysis	
has	unearthed	a	subtle	but	potentially	important	finding.		
There	 are	 a	 number	 of	 reasons	why	 these	 two	 outcomes	may	 differ.	 Firstly,	 “response”	 is	 a	much	
more	general	outcome	than	“cure”.	To	be	defined	as	responding	positively	to	a	treatment	regimen	a	
participant	 merely	 has	 to	 show	 some	 sign	 of	 improvement,	 be	 that	 biochemically,	 radiologically	
and/or	 clinically.	 This	 outcome	 is	 much	more	 open	 to	 researcher	 interpretation	 than	 “cure”	 were	
generally	all	signs	of	the	original	 infection	need	to	have	resolved.	This	 leads	on	to	the	second	point,	
even	a	 sub-optimal	 treatment	may	 lead	 to	a	positive	 clinical	 response	and	 therefore	 improvement.	
This	potentially	generates	background	noise;	 in	groups	of	 less	severely	unwell	patients,	 just	 looking	
for	 a	 positive	 response	 might	 not	 provide	 a	 rigorous	 enough	 test	 of	 the	 different	 administration	
methods	to	identify	significant	differences	in	efficacy.	
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Another	 important	 consideration	 is	 the	 RCTs	 themselves;	 eleven	 reported	 clinical	 cure	 and	 12	
reported	clinical	response	but	only	3	RCTs	reported	both	outcomes	(Nicolau	et	al.,	2001;	Roberts	et	
al.,	 2007;	 Chytra	 et	 al.,	 2012).	 Considering	 the	 limited	 overlap	 there	 may	 have	 been	 fundamental	
differences	between	the	2	sets	of	RCTs,	such	as	choice	of	antibiotic	or	patient	group,	that	account	for	







based	 on	 local	 resistance	 patterns.	 One	 such	 article	 (Abdul-Aziz	 et	 al.,	 2016)	 also	 reports	 the	
breakdown	of	outcomes	by	 individual	antibiotic.	The	authors	of	two	further	articles	were	contacted	
and	were	 able	 to	 supply	 detailed	 breakdown.	 From	 these	 three	RCTs	 a	 large	 amount	 of	 data	 from	
some	of	the	biggest	and	more	methodologically	robust	studies	was	available	for	analysis	by	antibiotic.	
Sub	 group	 analysis	 of	 individual	 antibiotics	 with	 respect	 to	 clinical	 cure	 revealed	 some	 interesting	
results	to	be	considered.		Firstly,	although	piperacillin,	a	penicillin,	had	shown	a	statistically	significant	
difference	between	the	administration	methods	the	bigger	the	study	the	 less	of	a	 favourable	effect	
was	 found	 hence	 the	 unfavourable	 heterogeneity	 (I2	 =	 31.9%).	 The	 second	 observation	 was	 that	
clinical	cure	with	different	methods	of	meropenem	administration	was	not	statistically	significant;	this	
raises	 the	 question	 of	 whether	 all	 β-lactams	 are	 “equal”	 and	 if	 studies	 should	 be	 investigating	
individual	antibiotics	rather	than	broader	classes.	This	later	consideration	is	potentially	supported	by	
the	 literature.	 It	 has	 been	 suggested	 that	 the	 amount	 of	 time	 different	 antibiotics	 need	 to	 spend	
above	the	MIC	in	each	dosing	interval	varies	with	penicillins	(e.g.	piperacillin)	requiring	greater	time	
above	 the	MIC	 than	 carbapenems	 (e.g.	meropenem)	 (Drusano,	 2004).	 It	 is	 possible	 that	 a	 positive	
effect	 from	one	 class	 is	muted	 by	 an	 underwhelming	 effect	 by	 others.	 It	 is	 possible	 that	 a	 greater	
beneficial	effect	may	be	seen	with	longer	infusions	of	penicillins	compared	to	other	β-lactams.	
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Clinical	heterogeneity,	 the	differences	 in	design,	participants,	 interventions,	 etc	between	 studies,	 is	
low.	The	articles	predominantly	investigate	continuous	infusions	of	β-lactams	and	were	published	in	
the	last	decade.	The	risk	of	statistical	heterogeneity,	detectable	if	the	variation	between	the	results	of	
the	 studies	 is	 greater	 than	 that	 expected	 by	 chance,	 is	 low.	 Visual	 assessment	 of	 the	 funnel	 plot	
looking	for	publication	bias	reveals	asymmetry	with	a	lack	of	studies	on	the	left-hand	side.	Using	the	
trim	 and	 fill	 method	 (Duval	 and	 Tweedie,	 2000)	 to	 impute	 missing	 studies	 identifies	 4	 possible	























Analysis	 including	 all	 antibiotics	 found	 no	 difference	 in	 mortality	 between	 the	 two	 methods	 of	
administration	 but	 analysis	 of	 just	 time-dependent	 action	 antibiotics	 revealed	 a	 positive	 benefit	
associated	with	extended	infusions.	Of	the	antibiotics	analysed	individually	this	benefit	was	also	seen	
within	 the	 ceftazidime	 sub	 group,	 however	 this	 secondary	 result	 should	be	 viewed	with	 caution	 as	
only	one	ceftazidime	article	(Angus	et	al.,	2000)	reported	mortality	and	the	total	number	of	patients	
analysed	for	this	outcome	was	only	21.		
Twenty	 three	articles	 reported	mortality	 as	 an	outcome	but	 the	 relative	weighting	allocated	 to	 the	
papers	meant	 that	 slightly	 over	 50%	of	 the	 effect	 seen	 in	 the	meta-analysis	 of	 all	 antibiotics	 came	
from	just	2	articles	(Dulhunty	et	al.,	2015;	Fan	et	al.,	2017).	When	the	19	articles	investigating	time-
dependent	 action	 antibiotics	were	 analysed	 alone,	 4	 articles	 accounted	 for	 over	 80%	 of	 the	 effect	
with	the	papers	by	Dulhunty	et	al	and	Fan	et	al	accounting	for	approximately	30%	each	and	two	more	
articles	contributing	11%	each	(Chytra	et	al.,	2012;	Abdul-Aziz	et	al.,	2016).	These	4	articles	all	report	
large,	 well-conducted	 RCTs	 published	 recently	 focusing	 predominantly	 on	 meropenem	 and	
piperacillin/tazobactam.	
Unfortunately	there	was	a	 lot	of	clinical	heterogeneity	between	the	articles.	Mortality	was	reported	
over	 different	 time	 frames,	 some	 relating	 to	 variable	 time	 frames	 such	 as	 “ICU	 mortality”	 and	
“hospital	 discharge”	and	others	picking	a	 specific	point	 in	 time,	 for	example	 “90	days”.	 In	 a	 similar	
way	to	 the	reporting	of	AE,	articles	also	varied	 in	whether	 they	reported	every	death	 i.e.	“all-cause	








Secondary	 and	 super-infection	 were	 included	 as	 reported	 in	 the	 articles	 and	 their	 incidence	 was	







It	 may	 add	 some	 detail	 to	 the	 more	 general	 outcome	 of	 clinical	 cure/response/failure	 but	 ideally	
future	studies	should	only	report	this	outcome	for	patients	with	a	proven	organism	whom	have	then	






post	 therapy	 regardless	 of	 whether	 or	 not	 an	 organism	 has	 been	 isolated	 at	 any	 point	 during	 the	
study	through	to	just	reporting	the	recurrence	of	the	originally	isolated	and	treated	organism.	These	
differences	 again	 make	 interpreting	 the	 combined	 results	 difficult	 and	 future	 systematic	 reviews	
could	afford	to	be	very	specific	a	priori	about	what	they	choose	to	include	in	the	meta-analysis.	
Bacteriological/microbiological	cure	
Many	 studies	didn’t	 report	 this	 outcome	and	where	 it	was	 reported	 the	numbers	of	 patients	were	
smaller	 than	the	total	enrolled	as	not	every	patient	had	a	verified,	culture	positive	 infection.	Again,	
the	 definition	 also	 varied	 from	 either	 proven	 eradication	 to	 overall	 eradication,	 the	 later	 including	
both	proven	and	presumed.	
Analysis	of	bacteriological/microbiological	cure	found	a	statistically	significant	difference	in	favour	of	
extended	 infusions	 when	 examining	 articles	 reporting	 results	 for	 both	 all	 antibiotics	 and	 time-
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dependent	 only	 antibiotics.	 However	 no	 difference	 between	methods	 of	 administration	was	 found	
when	antibiotics	where	examined	individual.	Interestingly	one	of	the	5	articles	accounted	for	83%	of	







systematic	 review	contains	eleven	more	articles	 than	 the	 last	 similarly	wide	 reaching	 review	of	 the	
literature	 conducted	 for	 the	 Cochrane	 Collaboration	 in	 2013	 (Shiu	 et	 al.,	 2013).	 This	 review	 also	
analyses	data	for	at	 least	an	additional	1700	patients	(approximately	1600	patients	in	the	review	by	




the	 Cochrane	 review	 and	 the	 results	 are	 almost	 identical.	 This	 systematic	 review	 focused	 on	 only	
articles	 or	 abstracts	 published	 in	 English	 and	 the	 published	 peer	 reviewed	 data	 contained	 within	
them,	 Shiu	 et	 al	 obtained	 translations	 of	 non-English	 papers	 and	 invited	 authors	 to	 contributed	
unpublished	 data.	 For	 the	 purpose	 of	 this	 review	 authors	 were	 only	 contacted	 for	 clarification	 of	
anomalies	in	the	data	or	for	subdivision	of	the	data	for	individual	antibiotics	where	it	was	published	
by	group	e.g.	β-lactams.		
There	 are	 2	main	 differences	 however	 between	 this	 systematic	 review	 and	 those	 that	 have	 come	
before	 it.	 Firstly,	 the	 definitions	 of	 the	 outcomes	 of	 interest	 set	 out	 a	 priori	 for	 the	 reviews	 and	
secondly	differences	 in	approach	 to	data	extraction.	For	example,	 this	 review	has	examined	clinical	
cure	rather	than	response	or	failure	leading	to	a	slightly	different	insight	into	the	results.	This	review	
has	 interpreted	 and	 analysed	 adverse	 events	 differently	 to	 previous	 reviews.	 Secondly,	 previous	
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reviews	have	treated	glycopeptides,	specifically	vancomycin,	as	 time-dependent	whereas	as	already	
discussed	 in	 this	 review,	 vancomycin	 has	 been	 excluded	 from	 the	 “time-dependent”	 analysis.	
Sensitivity	 analysis	 highlighted	 that	 this	 decision	 had	 an	 impact	 on	 the	 results,	mortality	 no	 longer	





This	 is	the	biggest	systematic	review	and	meta-analysis	to	date.	 It	 is	the	first	review	to	treat	clinical	
cure	 and	 clinical	 response	 as	 separate	 outcomes.	 In	 doing	 so	 it	 has	 highlighted	 a	 significant	 result	
when	 specifically	 looking	at	 articles	 that	 reported	 clinical	 cure	as	apposed	 to	assessing	 clinical	 cure	
and	 response	 under	 the	 same	 umbrella.	 In	 addition,	 this	 review	 has	 highlighted	 other	 previously	
unseen	improvements	in	bacteriological	cure	rates	and	mortality.	In	doing	so	it	has	shown	that	there	
truly	 is	 potential	 benefits	 from	 extended	 infusions.	 Sub	 group	 analysis	 of	 individual	 antibiotics	
however	 has	 highlighted	 the	 potential	 folly	 of	 the	 new	 trend	 to	 investigate	 β-lactams	 rather	 than	
individual	antibiotics	and	indicated	the	areas	that	future	studies	should	focus.	
4.5.4		 Limitations	and	assumptions	
Although	 statistical	 heterogeneity	was	 generally	 low	 or	 non-existent	 throughout	 this	meta-analysis	
clinical	and	methodological	heterogeneity	will	have	been	very	high.	Firstly,	these	articles	span	over	40	
years	 in	 which	 many	 aspects	 of	 clinical	 care	 have	 changed	 including	 effectiveness	 of	 other	 drug	
interventions,	accuracy	and	types	of	monitoring	equipment,	quality	of	nursing	interventions	and	even	
disease	definitions.	Secondly,	there	were	many	differences	throughout	the	articles	included	in	terms	
of	 definitions	 of	 the	 various	 outcomes	 and	 how	 outcome	 measures	 were	 applied.	 This	 makes	
generalising	 the	outcomes	very	difficult.	Many	outcomes	were	 reported	over	different	 time	 frames	
e.g.	mortality	reported	at	ICU	discharge,	hospital	discharge,	30	days,	90	days	or	without	a	stipulated	
time	frame.	An	example	of	how	this	may	affect	the	overall	outcome	can	be	seen	in	the	BLING	II	study	
(Dulhunty	 et	 al.,	 2015),	 hospital	mortality	was	 statistically	 significant	 but	was	 no	 longer	 significant	
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when	assessed	at	90	days.	Another	example,	 this	 time	of	data	unavailable	 for	 the	meta-analysis,	 is	







infusions	 of	 antibiotics	 in	 adult	 patients	 with	 presumed	 or	 proven	 sepsis.	 Statistically	 significant	
differences	in	clinical	cure	and	microbiological/bacteriological	cure	were	found	in	favour	of	extended	
infusion	 methods.	 No	 difference	 in	 adverse	 events	 was	 identified	 between	 the	 administration	
methods.	 Although	 a	 difference	 in	 mortality	 was	 seen	 when	 time-dependent	 antibiotics	 were	
analysed	 separately	 this	 result	 may	 have	 been	 influenced	 by	 the	 choice	 of	 method	 of	 statistical	
analysis.	Sub	group	analysis	showed	statistically	significant	differences	in	benefits	between	antibiotics	

















randomised	controlled	trials	 (RCTs)	 in	the	published	 literature	and	with	knowledge	of	the	articles	 in	
the	 pipeline	 at	 the	 time	 it	 was	 decided	 to	 update	 the	 review	 in	 April	 2018.	 A	 meta-analysis	 was	
performed	 investigating	 the	evidence	base	 for	all	antibiotics	and	sub-group	analysis	 focused	on	 the	
antibiotics	 shown	 by	 the	 survey	 to	 be	 given	 commonly	 on	 UK	 CCUs	 by	 extended	 methods	 of	
administration.	
5.1	 Overview	
The	results	of	both	phases	of	 the	study	have	shown	a	wide-ranging	 interest	 in	 the	 literature	and	 in	
practice	 for	 extended	methods	 of	 administration.	 Aside	 from	 the	 RCTs	 described	 in	 the	 systematic	
review	there	is	a	large	number	of	observational	studies	in	patients	and	pk/pd	studies	in	both	animal	
models	and	humans	that	have	shown	a	scientific	basis	for,	and	a	potential	benefit	to	be	gained	from,	
extending	 the	 duration	 over	 which	 an	 antibiotic	 infusion	 is	 administered.	 The	 systematic	 review	
revealed	 that	 the	 focus	 of	 the	 literature	 is	 predominantly	 on	 β-lactam	 antibiotics	 and	 although	
extended	 infusions	of	antibiotics	 in	 this	class	are	popular,	vancomycin	 is	by	 far	 the	most	commonly	
administered	extended	infusion	in	practice	across	CCUs	in	the	UK.	This	is	despite	there	being	only	two	
RCTs	assessing	 its	 safety	and	only	one	 (Wysocki	et	al.,	2001)	 investigating	efficacy,	 compared	 to	14	









beginning	 of	 2017.	 The	 survey	 of	 practice	 conducted	 at	 the	 end	of	 2013	 revealed	 that	 those	 CCUs	
using	 extended	methods	 of	 administration	 exclusively	 used	 EIIs	 for	 β-lactams	 and	 vancomycin	was	
given	only	by	CI.	These	findings	were	not	anticipated	during	the	study	design	phase	and	therefore	the	
questionnaire	 was	 not	 designed	 to	 collect	 data	 to	 investigate	 this	 aspect	 further.	 The	 following	





infusions	given	every	8	hours	 to	treat	Pseudomonas	aeruginosa	 infection	 (Lodise	et	al.,	2007a).	The	
two	groups	comprised	194	patients	 in	total	and	the	authors	state	the	groups	were	evenly	matched.	
Even	 though	 a	 lower	 total	 daily	 dose	 of	 antibiotic	was	 used	 in	 the	 EII	 group	 this	 group	 had	 better	












This	 has	 not	 yet	 been	widely	 investigated	 but	 for	 example	 one	 study	 has	 shown	 that	meropenem	
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1g/100mL	of	diluent	is	only	stable	at	25oC	for	12	hours	and	then	degrades	(Berthoin	et	al.,	2010)	and	








of	 time	 they	 spend	above	 the	minimum	 inhibitory	 concentration	 (T>MIC).	 Since	 their	 release	on	 to	
the	world	market,	piperacillin	and	meropenem	have	formed	the	mainstay	of	empirical	treatment	for	





Piperacillin,	 in	 all	 but	 one	 instance	 combined	 with	 tazobactam,	 was	 both	 the	 most	 commonly	
investigated	 antibiotic	 in	 the	 RCTs	 included	 in	 the	 systematic	 review.	 It	 is	 also	 the	 β-lactam	most	
commonly	administered	by	an	extended	infusion	method	on	UK	CCUs.	Meropenem,	although	third	in	
terms	 of	 the	 number	 of	 published	 RCTs,	was	 usually	 prescribed	 for	 extended	 infusion	 on	 a	 similar	
number	of	CCUs	as	piperacillin.	In	total,	across	all	of	the	patients	enrolled	in	the	RCTs,	approximately	
1400	received	piperacillin	and	more	than	500	received	meropenem.	Between	them	they	accounting	
for	nearly	2/3	of	 the	 total	number	of	patients	 investigated	 in	 the	studies.	These	two	antibiotics	are	
now	 commonly	 being	 investigated	 in	 the	 same	 studies	 under	 the	 umbrella	 term	 of	 β-lactams	
(Dulhunty	et	al.,	2015;	Abdul-Aziz	et	al.,	2016).		
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time-dependent	 action	 antibiotics,	 a	 reduction	 in	 mortality,	 and	 improved	
microbiological/bacteriological	 cure	 rates	 over	 standard	 methods,	 but	 no	 difference	 between	
administration	methods	for	any	of	the	adverse	events.	All	but	one	of	the	articles	included	in	the	time-
dependent	 analysis	 investigated	β-lactams,	 however	 individual	 analysis	 by	 antibiotic	 failed	 to	 show	
any	positive	difference	in	any	outcomes	for	meropenem,	and	only	a	superior	clinical	cure	rate	but	no	
mortality	benefit	for	piperacillin/tazobactam.			
Another	 point	 of	 note	 is	 that,	 as	 described	 above,	 the	 majority	 of	 articles	 reported	 studies	
investigating	 continuous	 infusions	 but	 all	 of	 the	 practice	 in	 UK	 CCUs	 for	 these	 two	 antibiotics	 is	
extended	intermittent	infusions.	
Although	the	evidence	base	points	towards	a	benefit	from	extended	infusions,	the	articles	included	in	





survey	showed	 that	 they	are	by	 in	 far	 the	most	popular	extended	 infusion	being	given	on	UK	CCUs	
and	the	only	antibiotic	given	by	CI.	50%	of	CCUs	give	vancomycin	by	extended	infusion	with	the	next	
most	popular	antibiotic,	piperacillin/tazobactam,	being	given	on	just	over	20%.		
As	 previously	 described	 vancomycin	 pk/pd	 still	 isn’t	 fully	 understood	 (Löwdin	 et	 al.,	 1998;	 Moise-
Broder	et	 al.,	 2004;	Vandecasteele	et	 al.,	 2012).	 It	 is	 now	widely	 accepted	 that	 although	 it	 exhibits	
elements	 of	 both	 time-	 and	 concentration-dependent	 action	 the	 pk/pd	 parameter	 that	 best	 aligns	
with	 efficacy	 is	 the	 total	 exposure	 over	 time	 (AUC:MIC	 ratio)	 (Holmes	 et	 al.,	 2013).	 Although	 this	
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systematic	 review	 only	 found	 two	 RCTs	 there	 have	 been	many	 other	 articles	 reviewing	 the	 use	 of	
vancomycin	 as	 a	 CI.	 Even	 though	 to	 date	 no	 benefit	 in	 efficacy	 has	 been	 shown,	 CIs	 appear	 to	 be	
simpler	to	administer,	cheaper	and	have	less	adverse	events	(Cataldo	et	al.,	2012;	Hao	et	al.,	2016).	
The	 responses	 to	 the	questionnaire	 confirm	 that	 these	 factors	have	been	 taken	 into	account	when	
adopting	this	practice.	
The	 benefits	 largely	 revolve	 around	 the	 ability	 to	 do	 therapeutic	 drug	monitoring	 (TDM)	 of	 serum	
vancomycin	 levels.	Unlike	 the	β-lactams,	which	 as	 a	 general	 rule,	 have	 a	 large	 therapeutic	window	
and	are	generally	deemed	to	be	safe,	vancomycin	has	a	narrow	therapeutic	window	and	overdose	or	
accumulation	 can	 lead	 to	 severe	 complications	 such	 as	 nephrotoxicity.	 Due	 to	 vancomycin’s	 side	
effect	 profile	 TDM	 has	 always	 been	 both	 advisable	 and	 readily	 available	 in	 all	 clinical	 situations	 in	
which	 vancomycin	 is	 used	 in	 the	 UK.	 As	 shown	 in	 the	 survey,	 TDM	 is	 used	 ubiquitously	 in	 the	
management	of	patients	on	vancomycin	throughout	UK	CCUs.		
CIs	allow	dosing	and	administration	to	be	simplified.	This	not	only	makes	the	job	of	the	nursing	staff	
easier,	 but	 also	 removes	 any	 elements	 of	 doubt	 in	 the	 pharmacist’s	mind	when	 trying	 to	 interpret	
TDM	levels,	which	are	otherwise	more	complex	with	standard	intermittent	dosing.		
Another	 important	 factor	 is	 safety.	A	study	 in	2009	showed	that	nephrotoxicity	 increases	as	 trough	
vancomycin	 levels	 increase	 in	 patients	 receiving	 standard	 dosing.	 A	 5%	 incidence	 was	 seen	 when	
initial	trough	was	<10	mg/L	compared	with	33%	if	the	trough	was	>20	mg/L	(Lodise	et	al.,	2009).	This	
is	worrying	as	 target	 levels	of	15-25mg/L	are	often	used	 in	CI	protocols	 (James	et	al.,	1996;	Barton,	
2009)	 but	 the	 negative	 effect	 observed	may	be	due	 to	 higher	 peak	 concentrations	 associated	with	
high	troughs	or	a	larger	AUC:MIC	ratio	rather	than	the	trough	per	se.	This	is	supported	by	a	number	of	
studies	 and	 reviews	 that	 have	 shown	 a	 lower	 incidence	 of	 nephrotoxicity	 with	 CIs	 compared	 to	
intermittent	infusions	(Schmelzer	et	al.,	2013;	Tafelski	et	al.,	2015;	Hao	et	al.,	2016).	













appears	 to	 be	 shown	 in	 using	 them	 as	 extended	 infusions	 on	 UK	 CCUs.	 From	 the	 results	 of	 the	
questionnaire	 it	 is	 apparent	 that	 the	 only	 CCUs	 using	 any	 other	 β-lactam	 antibiotics	 by	 extended	
infusions	are	large	Trusts	with	multiple	CCUs,	a	lot	of	level	3	beds	and	a	senior	pharmacist	integrated	
into	 the	 CCU	 team.	 There	 may	 be	 two	 reasons	 for	 this;	 the	 first	 is	 that	 meropenem	 and	
piperacillin/tazobactam	 are	 used	 empirically	 for	 a	 wide	 range	 of	 suspected	 micro-organisms	 and	
source	 sites.	 Most	 of	 the	 other	 β-lactams	 are	 used	 for	 very	 specific	 infections,	 for	 example	
flucloxacillin	 for	 a	 suspected	 staphylococcal	 spp.	 soft	 tissue	 infection.	 With	 this	 in	 mind	 even	 the	
smallest	CCU	will	 frequently	use	piperacillin/tazobactam	and	meropenem	but	may	rarely	 if	ever	use	
some	of	the	more	niche	β-lactams.	The	second	possible	reason	is	related	to	the	first;	the	largest	CCUs	
which	 are	 administering	 piperacillin/tazobactam	 and	meropenem	 by	 EII	 will	 also	 use	 a	 number	 of	
other	β-lactams	by	nature	of	their	size	and	specialist	areas,	e.g.	neurology,	cardiothoracics,	etc.	They	
therefore	may	approach	 the	 subject	 in	a	more	enthusiastic	manner	developing	guidelines	 for	 all	 of	
the	 β-lactams	 they	use	 commonly	 across	 the	 larger	 departments.	However,	 big	 doesn’t	 necessarily	
mean	 better;	 flucloxacillin	 is	 reportedly	 used	 in	 one	 Trust	 on	 its	 4	 CCUs	 despite	 there	 not	 being	 a	
single	RCT	investigating	its	efficacy	or	safety.	
5.6	 Professional	influence	on	the	adoption	of	extended	administration	methods		
The	 adoption	 of	 extended	 infusions	 of	 antibiotics	 correlates	 with	 whether	 or	 not	 the	 CCU	 has	 an	
experienced	 pharmacist(s)	 integrated	 into	 the	 team,	 attending	multi-professional	ward	 rounds	 and	
providing	seven-day	service.	This	could	be	an	unforeseen	advantage	of	having	a	senior,	experienced	
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revealed	 that	 this	 was	 less	 convincing	 in	 more	 specific	 areas.	 Despite	 this,	 many	 CCUs	 are	 using	
extended	infusions,	so	one	is	led	to	ask	if	there	is	a	risk	of	this	resulting	in	patient	harm.	The	evidence	
from	 the	 RCTs	 suggests	 not,	 the	 overall	 outcomes	 suggested	 that	 at	 worst	 there	 is	 no	 difference	





aeruginosa	 or	 in	 the	 case	 of	 vancomycin	 methicillin	 resistant	 staphylococcus	 aereus,	 but	 many	
critically	 ill	 patients	 do	 not	 have	 these	 infection.	 Articles	 frequently	 reported	 exclusion	 of	 patients	
from	the	study	who	had	renal	failure,	but	these	patients	form	a	large	cohort	of	the	patients	that	are	
to	 be	 found	 every	 day	 on	 CCUs.	 Some	 of	 the	 responses	 to	 the	 questionnaire	 addressed	 this	 and	
although	extended	infusions	may	not	be	used	by	some	in	their	regular	practice,	patients	treated	with	
extended	 infusions	 may	 be	 considered	 to	 be	 at	 high	 risk	 of	 renal	 failure,	 especially	 those	 with	





only	 ever	 been	 available	 for	 drugs	 with	 poor	 side	 effect	 profiles	 such	 as	 vancomycin	 and	 the	





point-of-care	 system	 that	 would	 facilitate	 rapid	 turnaround	 of	 results	 to	 guide	 therapy	 in	 a	
meaningful	 way.	 This	 could	 be	 used	 in	 combination	 with	 knowledge	 of	 the	 MIC	 of	 the	
antibiotic/micro-organism	combination	the	clinician	is	faced	with,	to	then	tailor	the	antibiotic	therapy	
for	the	patient	being	treated.	What	this	would	mean	is	that	for	the	most	part	patients	would	receive	
antibiotics	 by	 licensed	 administration	 methods	 or	 where	 extended	 infusions	 are	 usual	 practice	
therapy	can	be	rationalised.	
5.10	 Limitations	
The	 most	 important	 potential	 limitation	 in	 this	 study	 is	 the	 time	 between	 the	 two	 elements,	 the	
questionnaire	was	launched	towards	the	end	of	2013	and	the	meta-analysis	completed	in	April	2018.	
Just	by	looking	at	the	number	of	new	RCTs	published	in	the	last	5	years	it	is	evident	that	the	level	of	
interest	 is	 growing.	 In	 line	with	 this,	 anecdotally	 the	 number	 of	 posts	 on	 the	UKCPA	CCG	message	








statistical	 heterogeneity	 or	 statistical	 need	 for	 further	 research.	 However	 there	 is	 a	 big	 but	 and	 it	
surrounds	 the	 clinical	 heterogeneity	 in	 the	 articles.	 There	 is	 a	 lot	 of	 diversity	 in	 the	 antibiotics	
investigated,	the	underlying	condition	being	treated,	the	target	microorganisms	and	the	use	of	non-
study	 antibiotics	 to	 name	 just	 a	 few	 variables.	 To	 add	 to	 this	 many	 studies	 pre-date	 both	 the	





The	 β-lactam	 infusion	 study	 group	 (BLING)	 are	 just	 starting	 to	 enrol	 on	 their	 phase	 III	 randomised	
controlled	 trial	 of	 continuous	 β-lactam	 infusions	 compared	 with	 intermittent	 β-lactam	 dosing	 in	
critically	ill	patients	(BLING	III).	This	study	aims	to	enroll	7000	patients	across	100	CCUs	worldwide	and	
give	the	definitive	answer	to	the	question	do	CIs	of	β-lactam	antibiotics	improve	mortality.	The	study	
hopes	 to	complete	enrollment	at	 the	end	of	2021.	Even	 this	major	study	will	 leave	some	questions	
unanswered	 though.	 Firstly	 the	 group	 are	 investigating	 CIs	 so	 the	 question	 will	 remain	 over	 the	
efficacy	 and	 safety	 of	 EIIs,	 which	 are	 currently	 commonly	 used	 on	 UK	 CCUs.	 Again	 piperacillin	 (a	
penicillin)	 and	meropenem	 (a	 carbopenem)	 are	 lumped	 together	 as	 “β-lactams”	 and	 how	 this	 will	
affect	the	results	is	unknown,	as	the	meta-analysis	in	chapter	4	has	shown	there	may	be	an	argument	
for	 investigating	 antibiotics	 individually.	 This	 study	 will	 only	 answer	 the	 question	 about	 the	
effectiveness	of	the	antibiotics	it	 investigates	so	further	studies	will	be	required	to	investigate	other	
agents	 but	most	 notably	 vancomycin.	 Lastly	 BLING	 III	may	 struggle	 to	 recruit	 to	 schedule	 as	many	












Current	UK	critical	care	practice	of	 intravenous	antibiotic	administration	 is	 in	 line	with	the	evidence	
base.	 This	 meta-analysis	 shows	 that	 extended	 infusions	 are	 both	 safe	 and	 at	 least	 as	 effective	 as	








Vancomycin	 is	 given	as	a	CI	on	approximately	50%	of	UK	CCUs	and	although	 there	are	only	2	RCTs	
investigating	its	administration	by	this	method	factors	other	than	just	efficacy	have	been	sited	for	its	
adoption.	 It	 is	 perceived	 to	 be	 easier	 to	manage	 and	 has	 been	 proven	 to	 have	 less	 nephrotoxicity	
when	administered	in	this	way.	
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There	 is	 growing	 interest	 in	 the	 use	 of	 novel	 methods	 of	 administration	 to	 improve	 existing	
antibiotics	 effectiveness	 in	 a	 time	 when	 very	 few	 new	 antibiotics	 are	 entering	 the	market.	 This	
study	is	being	undertaken	to	investigate	current	standard	antibiotic	administration	practices	across	
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Appendix	7:	Definitions	of	low,	high	and	unclear	risk	of	bias	for	each	category	Sequence	generation	(selection	bias)	 Was	sequence	generation	adequate?	 Low	risk	 Random	sequence	generation	is	described	(for	example	by	computer	generation	or	random	number	tables)	High	risk	 Sequence	generation	is	in	part	or	completely	non-randomised	(for	example	patients	allocated	by	clinician	or	order	of	admission	into	the	study)	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Allocation	concealment	(selection	bias)	
Was	allocation	concealment	adequate?	 Low	risk	 Neither	patients	nor	enrolling	investigators	could	predict	assignment	(e.g.	opaque	sealed	envelopes,	off-site	randomisation)	High	risk	 Either	patients	and	or	enrolling	investigators	could	predict	assignment	(e.g.	unsealed	envelopes,	alternation,	allocation	by	patient	identifier	e.g.	hospital/NHS	number)	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Blinding	of	participants	and	personnel	(performance	bias)	
Was	blinding	of	participants	and	personnel	adequate?	 Low	risk	 Blinding	of	patients	and	key	study	personnel	stated	and	appears	to	be	robust	High	risk	 No	or	incomplete	blinding,	or	blinding	attempted	but	likely	to	have	been	broken	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias		 	 	 	
	 168	
Blinding	of	outcome	assessment	(detection	bias)	


















• Study	report	fails	to	include	results	for	a	key	outcome	that	would	be	expected	to	have	been	reported	for	such	a	study	Unclear	 Insufficient	information	to	judge	low	or	high	risk	of	bias	Other	bias	 Was	study	free	from	other	potential	sources	of	bias	not		covered	elsewhere	

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































39	 70	 24	 70	 	 	 	 	
	 	 	 	 Pip/taz	 	 	 22	 38	 15	 47	 	 	 	 	
	 	 	 	 Mero	 	 	 14	 21	 8	 21	 	 	 	 	
	 	 	 	 Cefepime	 	 	 3	 11	 1	 2	 	 	 	 	
	 	 	 	 ICU-free	days	(2)	 	 Median		 	 	 	 	 20	 	 17	 	
	 	 	 	 ventilator	free	days	(2)	 	 Median		 	 	 	 	 22	 	 14	 	
	 	 	 	 Survival	at	14/7	(2)	 	 actual	
numbers	
56	 70	 50	 70	 	 	 	 	
	 	 	 	 Survival	at	30/7	(2)	 	 actual	
numbers	
52	 70	 44	 70	 	 	 	 	
	 	 	 	 AE	(-)	 	 actual	
numbers	
0	 70	 0	 70	 	 	 	 	
Adembri	
2008	
Linezolid	 T	 CI	 Clinical	Cure	(1?)	 PP	 actual	
numbers	
6	 8	 6	 8	 	 	 	 	
	 	 	 	 Microbiological	Cure	(1?)	 PP	 actual	
numbers	
8	 9	 7	 11	 	 	 	 	
Angus	
2000	
Ceftazidime	 T	 CI	 All	cause	mortality	(-)	 *	 actual	
numbers	
3	 10	 9	 11	 	 	 	 	
Bodey	
1979	
C/C	 T	 CI	 Cure	 data	from	episodes	not	
patients	therefore	excluded	
from	MA	
	 	 	 	 	 	 	
	 	 	 	 Relapse	 	 	 	 	 	 	 	 	 	 	























Buck	2005	 P/T	 T	 CI	 Responsea	 ITT	 actual	
numbers	
8	 12	 8	 12	 	 	 	 	
Chytra	
2012	




88	 120	 81	 120	 	 	 	 	




88	 106	 81	 108	 	 	 	 	
	 	 	 	 Clinical	Cure	 ITT	 actual	
numbers	
30	 120	 24	 120	 	 	 	 	
	 	 	 	 Clinical	Cure	 CE	 actual	
numbers	
30	 106	 24	 108	 	 	 	 	
	 	 	 	 post	hoc	sub	groups	(1)	 all	PP	 actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 1a)	cultures	based	 	 	 86	 100	 75	 101	 	 	 	 	
	 	 	 	 1b)	Empirical	 	 	 4	 6	 6	 7	 	 	 	 	
	 	 	 	 2)without	conc.	Abx	tx	
against	G-	
	 	 80	 95	 76	 102	 	 	 	 	
	 	 	 	 3)	APACHE	II	>20	 	 	 37	 49	 42	 53	 	 	 	 	
	 	 	 	 4)	MIC	>	or	=1.5mg/L	 	 	 10	 14	 12	 21	 	 	 	 	
	 	 	 	 Microbiological	Cure	(1)	 PP	 actual	
numbers	
87	 96	 80	 102	 	 	 	 	
	 	 	 	 i)	verified	 	 	 67	 96	 62	 102	 	 	 	 	
	 	 	 	 ii)	presumed	 	 	 20	 96	 18	 102	 	 	 	 	
	 	 	 	 post	hoc	sub	groups	(1)	 all	PP	 actual	
numbers	
	 	 	 	 	 	 	 	
	 	 	 	 1a)	cultures	based	 	 	 82	 90	 74	 95	 	 	 	 	
	 	 	 	 1b)	Empirical	 	 	 5	 6	 5	 7	 	 	 	 	
	 	 	 	 2)without	conc.	Abx	tx	
against	G-	

























M	 T	 CI	 3)	APACHE	II	>20	 	 	 41	 47	 36	 49	 	 	 	 	
	 	 	 	 4)	MIC	>	or	=1.5mg/L	 	 	 11	 14	 13	 21	 	 	 	 	




	 	 	 	 	 	 	 	 	
	 	 	 	 1)	mechanical	vent.	(2)	 ITT	 Median		 	 	 	 	 9	 	 11	 	
	 	 	 	 	 PP	 	 	 	 	 	 9	 	 12	 	
	 	 	 	 2)	ICU	stay,	LOS	(2)	 ITT	 Median		 	 	 	 	 10	 	 12	 	
	 	 	 	 	 PP	 	 	 	 	 	 10	 	 13	 	
	 	 	 	 3)	Hospital	stay,	LOS	(2)	 ITT	 Median		 	 	 	 	 26	 	 22	 	
	 	 	 	 	 PP	 	 	 	 	 	 28	 	 25	 	
	 	 	 	 ICU	mortality	(2)	 ITT	 actual	
numbers	
18	 120	 25	 120	 	 	 	 	
	 	 	 	 	 PP	 	 14	 106	 17	 108	 	 	 	 	
	 	 	 	 in	hospital	mortality	(2)	 ITT	 actual	
numbers	
21	 120	 28	 120	 	 	 	 	
	 	 	 	 	 PP	 	 17	 106	 19	 108	 	 	 	 	
	 	 	 	 duration	of	M	tx	(2)	 ITT	 Median	
(days)	
	 	 	 	 7	 	 8	 	
	 	 	 	 	 PP	 	 	 	 	 	 7	 	 8	 	
	 	 	 	 total	M	dose	(2)	 ITT	 Median	
(dose	in	
g)	
	 	 	 	 24	 	 48	 	
	 	 	 	 	 PP	 	 	 	 	 	 24	 	 48	 	




10	 120	 12	 120	 	 	 	 	





























M	 T	 CI	 Superinfection	(-)	 PP	 actual	
numbers	








26	 40	 32	 38	 	 	 	 	




7	 40	 12	 38	 	 	 	 	




2	 32	 2	 25	 	 	 	 	




2	 32	 2	 25	 	 	 	 	




	 	 	 	 3	 	 3	 	




18	 33	 17	 29	 	 	 	 	




	 	 	 	 2	 	 3	 	




8	 40	 11	 38	 	 	 	 	
	 	 	 	 Antibiotic-free	periodd	(2)	 ITT	 	 	 	 	 	 	 	 	 	
De	Jongh	
2008	




6	 6	 6	 6	 	 	 	 	
	 	 	 	 survival	at	28	days	(-)	 **	 actual	
numbers	
6	 6	 6	 6	 	 	 	 	
Dulhunty	
2013	




23	 30	 15	 30	 	 	 	 	
	 	 	 	 ICU	mortality	(2)e	 ITT	 actual	
numbers	
























P/T,	M,	T/C	 T	 CI	 in	hospital	mortality	(2)e	 ITT	 actual	
numbers	
3	 30	 6	 30	 	 	 	 	
	 	 	 	 ICU-free	days	(2)	 ITT	 Median	
(days)	
	 	 	 	 19.5	 	 17	 	
	 	 	 	 Adverse	events	(2)	 ITT	 actual	
numbers	
0	 30	 0	 30	 	 	 	 	
Dulhunty	
2015	






	 	 	 	 18	 	 20	 	




	 	 	 	 21	 	 22	 	
	 	 	 	 Day	90	mortality	(2)	 	 actual	
numbers	
156	 212	 158	 220	 	 	 	 	
	 	 	 	 ICU	survival	(-)	 	 actual	
numbers	
180	 212	 182	 220	 	 	 	 	
	 	 	 	 Hospital	survival	(-)	 	 actual	
numbers	
168	 212	 164	 220	 	 	 	 	




111	 212	 109	 220	 	 	 	 	




	 	 	 	 6	 	 6	 	




	 	 	 	 0	 	 0	 	
	 	 	 	 ICU	length	of	stay	(-)	 	 Median	
(days)	
	 	 	 	 7	 	 6	 	
	 	 	 	 Hospital	length	of	stay	(-)	 	 Median	
(days)	
	 	 	 	 16	 	 14	 	
	 	 	 	 Adverse	events	(-)	 	 actual	
numbers	





























19	 212	 25	 220	 	 	 	 	




	 	 	 	 	 	 	 	
	 	 	 	 Mortality	(-)	 ITT	 actual	
numbers	
8	 63	 6	 57	 	 	 	 	
	 	 	 	 Superinfection	(1?)	 can't	find	 actual	
numbers	
	 	 	 	 	 	 	 	




	 	 	 	 	 	 	 	




10	 12	 17	 22	 	 	 	 	





2	 10	 5	 16	 	 	 	 	




2	 28	 6	 40	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT?	 actual	
numbers	
2	 30	 1	 40	 	 	 	 	
Georges	
2005	
Cefepime	 T	 CI	 Clinical	cure	(2?)	 PP	 actual	
numbers	
22	 26	 16	 24	 	 	 	 	
	 	 	 	 days	of	ventilation	(2?)	 PP	 Mean	
(days)	
	 	 	 	 24	 	 25	 	
	 	 	 	 days	on	ICU	(2?)	 PP	 Mean	
(days)	
	 	 	 	 34	 	 40	 	
	 	 	 	 Clinical	failure	(2?)	 PP	 actual	
numbers	
4	 26	 7	 24	 	 	 	 	
	 	 	 	 Bacteriological	cure	(2?)	 PP	 actual	
numbers	

























Cefepime	 T	 CI	 No	eradication	(2?)f	 PP	 actual	
numbers	
2	 26	 3	 24	 	 	 	 	
	 	 	 	 Failure	(2?)	 PP	 actual	
numbers	
1	 26	 2	 24	 	 	 	 	
	 	 	 	 Overinfection	(2?)	 PP	 actual	
numbers	
3	 26	 4	 24	 	 	 	 	
	 	 	 	 Mortality	(2?)	 PP	 actual	
numbers	
3	 26	 3	 24	 	 	 	 	
Hanes	
2000	
Ceftazidime	 T	 CI	 Clinical	response	(1?)g	 PP	 actual	
numbers	
9	 16	 10	 14	 	 	 	 	
	 	 	 	 superinfection	(-)	 PP	 actual	
numbers	
7	 16	 3	 14	 	 	 	 	
	 	 	 	 days	of	ventilation	(-)	 	PP	 Mean	
(days)	
	 	 	 	 13.3	 	 22.9	 	
	 	 	 	 days	on	ICU	(-)	 PP	 Mean	
(days)	
	 	 	 	 15.5	 	 26.8	 	
	 	 	 	 hospital	stay	(-)	 PP	 Mean	
(days)	
	 	 	 	 28.7	 	 41.7	 	
Lagast	
1983	
Cefoperazone	 T	 CI	 Clinical	cure	(1?)	 ITT	 actual	
numbers	
14	 20	 20	 25	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1?)h	 ITT	 actual	
numbers	
n/a	 n/a	 n/a	 n/a	 	 	 	 	
	 	 	 	 Superinfection	(1?)	 ITT	 actual	
numbers	
2	 20	 1	 25	 	 	 	 	
	 	 	 	 Death	(1?)	 ITT	 actual	
numbers	
5	 20	 4	 25	 	 	 	 	




























Temocillin	 T	 CI	 Clinical	cure	(-)	 ITT	 actual	
numbers	
13	 14	 11	 14	 	 	 	 	
	 	 	 	 Overall	ICU	mortality	(-)	 ITT	 actual	
numbers	
2	 14	 5	 14	 	 	 	 	
	 	 	 	 Adverse	reaction	(-)	 ITT	 actual	
numbers	
1	 14	 0	 14	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT	 actual	
numbers	
1	 14	 0	 14	 	 	 	 	
Lau	2006	 P/T	 T	 CI	 Clincal	success	(1)j	 mITT	 actual	
numbers	
96	 128	 104	 130	 	 	 	 	
	 	 	 	 	 CE	 actual	
numbers	
70	 81	 76	 86	 	 	 	 	
	 	 	 	 	 BE	 actual	
numbers	
46	 56	 49	 58	 	 	 	 	




47	 56	 51	 58	 	 	 	 	




















22	 130	 18	 132	 	 	 	 	
	 	 	 	 as	above	but	all	 mITT	 actual	
numbers	
116	 130	 115	 132	 	 	 	 	




2	 130	 1	 132	 	 	 	 	
	 	 	 	 as	above	but	all	 mITT	 actual	
numbers	
























	 T	 CI	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Lu	2013	 P/T	 T	 EII	 treatment	success		 ITT	 actual	
numbers	
22	 25	 20	 25	 	 	 	 	
	 	 	 	 Relapse	 ITT	 actual	
numbers	
1	 25	 2	 25	 	 	 	 	
Lubasch	
2003	
Ceftazidime	 T	 EII	 Clinical	outcome	(1)m	 ITT	 actual	
numbers	
37	 41	 36	 40	 	 	 	 	




37	 41	 35	 40	 	 	 	 	




	 	 	 	 	 	 	 	 	
McNabb	
2001u	
Ceftazidime	 T	 CI	 adverse	events	(-)	 ITT	 actual	
numbers	
11	 17	 13	 18	 	 	 	 	
	 	 	 	 Superinfection	(-)	 ITT	 actual	
numbers	
3	 17	 3	 18	 	 	 	 	
Nicolau	
1999b	
Ceftazidime	 T	 CI	 adverse	events	(-)	 ITT	 actual	
numbers	
0	 11	 0	 13	 	 	 	 	
Nicolau	
2001	




7	 17	 6	 18	 	 	 	 	





16	 17	 15	 18	 	 	 	 	




	 20	 	 31	 	 	 	 	





























Ceftazidime	 T	 CI	 microbiological	response	 BE	 actual	
numbers	
10	 13	 12	 15	 	 	 	 	
	 	 	 	 bacterial	eradication	(-)	 BE	 Average	
(days)	















	 	 	 	 ICU	length	of	stay	(-)	 CE	 Average	
(days)	








M	 T	 CI	 Efficacy	rate	(-)	 ?	 actual	
numbers	
20	 25	 19	 25	 	 	 	 	
	 	 	 	 bacterial	eradication	(-)	 ?o	 actual	
numbers	
11	 12	 15	 17	 	 	 	 	
Pedeboscq	
2001	
P/T	 T	 CI	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Rafati	
2006	





12	 16	 10	 12	 	 	 	 	
	 	 	 	 Mortality	(-)	 mITT	 actual	
numbers	
5	 20	 6	 20	 	 	 	 	
Roberts	
2007	
Ceftriaxone	 T	 CI	 Clinical	response	(1)p	 ITT	 actual	
numbers	
25	 29	 23	 28	 	 	 	 	
	 	 	 	 Clinical	cure	(1)	 ITT	 actual	
numbers	
13	 29	 5	 28	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1)q	 ITT	 actual	
numbers	

























Ceftriaxone	 T	 CI	 Superinfection	(1)	 ITT	 actual	
numbers	
1	 29	 2	 28	 	 	 	 	
	 	 	 	 Secondary	infection	(1)	 ITT	 actual	
numbers	
1	 29	 0	 28	 	 	 	 	
	 	 	 	 Clinical	response	(1)p	 PP	 actual	
numbers	
24	 25	 22	 25	 	 	 	 	
	 	 	 	 Clinical	cure	(1)	 PP	 actual	
numbers	
13	 25	 5	 25	 	 	 	 	
	 	 	 	 Bacteriological	cure	(1)q	 PP	 actual	
numbers	
18	 25	 14	 25	 	 	 	 	
	 	 	 	 Superinfection	(1)	 PP	 actual	
numbers	
1	 25	 2	 25	 	 	 	 	
	 	 	 	 Secondary	infection	(1)	 PP	 actual	
numbers	
1	 25	 0	 25	 	 	 	 	
	 	 	 	 mortality	(-)	 ITT	 actual	
numbers	
3	 29	 0	 28	 	 	 	 	





M	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
2	 5	 0	 5	 	 	 	 	
Roberts	
2009b	
P/T	 T	 CI	 Clinical	outcomer	 ITT	 actual	
numbers	
6	 6	 7	 7	 	 	 	 	
Roberts	
2010	
P/T	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
0	 8	 0	 8	 	 	 	 	
Sakka	
2007	
I/C	 T	 CI	 mortality	(outcome)	(-)	 ITT	 actual	
numbers	
1	 10	 2	 10	 	 	 	 	
	 	 	 	 ICU	LOS	(-)	 ITT	 Average	
(days)	



























I/C	 T	 CI	 Adverse	events	(-)	 ITT	 actual	
numbers	
0	 10	 0	 11	 	 	 	 	
Schmelzer	
2013	








Cefotaxime	 T	 CI	 Clinical	outcome	(1)s	 NE	 actual	
numbers	
37	 40	 40	 43	 	 	 	 	






	 	 	 	 	
	 	 	 	 AE	(-)	 NE	 actual	
numbers	
0	 40	 0	 43	 	 	 	 	
	 	 	 	 Mortality	(-)	 ITT	 actual	
numbers	
4	 47	 1	 46	 	 	 	 	
Wright	
1979	
Gentamicin	 C	 CI	 Mortality	(-)	 ITT	 actual	
numbers	
5	 23	 3	 13	 	 	 	 	
Wysocki	
2001	
Vancomycin	 MIC:AUC	 CI	 Efficacy	(1)t	 PP	 actual	
numbers	
48	 61	 47	 58	 	 	 	 	
	 	 	 	 Safety	(1)	 PP	 actual	
numbers	
12	 n/a	 12	 n/a	 	 	 	 	




10	 61	 11	 58	 	 	 	 	
	 	 	 	 mortality	(-)v	 PP	 actual	
numbers	
21	 61	 19	 58	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Bao	2017	 P/T	 T	 EII	 Clinical	outcome	(1)x	 PP	 actual	
numbers	
22	 25	 20	 25	 	 	 	 	
	 	 	 	 AE	(1)	 PP	 actual	
numbers	






















Bao	2017	 P/T	 T	 EII	 SAE	(-)	 PP	 actual	
numbers	
5	 25	 4	 25	 	 	 	 	
	 	 	 	 WAE	(-)	 PP	 actual	
numbers	
2	 25	 3	 25	 	 	 	 	
Fan	2017	 P/T	 T	 EII	 Mortality	14/7	(1)	 PP	 actual	
numbers	
21	 182	 29	 185	 	 	 	 	
	 	 	 	 Mortality	in	hospital	(2)	 PP	 actual	
numbers	
52	 182	 59	 185	 	 	 	 	




	 	 	 	 4	 	 6	 	




	 	 	 	 5	 	 5	 	
	 	 	 	 ICU	length	of	stay	(2)	 PP	 median	
(days)	
	 	 	 	 3	 	 4	 	




	 	 	 	 20	 	 21	 	
	 	 	 	 AE	(-)	 PP	 actual	
numbers	
0	 182	 0	 185	 	 	 	 	
Ram	2018	 P/T,	
ceftazidime	
T	 EII	 Overall	response	(1)y	 ITT	 actual	
numbers	
35	 47	 32	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
35	 43	 30	 48	 	 	 	 	
	 	 	 	 Clincal	failure	(1)z	 ITT	 actual	
numbers	
3	 47	 11	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
1	 43	 5	 48	 	 	 	 	
	 	 	 	 Fever	(2)	 ITT	 median	
(days)	
























T	 EII	 	 PP	 median	
(days)	
	 	 	 	 2	 	 2	 	
	 	 	 	 Noradrenaline	(2)	 ITT	 actual	
numbers	
4	 47	 10	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
2	 43	 4	 48	 	 	 	 	
	 	 	 	 AKI	(2)	 ITT	 actual	
numbers	
3	 47	 6	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
3	 43	 4	 48	 	 	 	 	
	 	 	 	 C.	diff	(2)	 ITT	 actual	
numbers	
0	 47	 2	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
0	 43	 2	 48	 	 	 	 	
	 	 	 	 breakthrough	BSI	(2)	 ITT	 actual	
numbers	
2	 47	 7	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
2	 43	 7	 48	 	 	 	 	




6	 47	 10	 58	 	 	 	 	
	 	 	 	 	 PP	 actual	
numbers	
5	 43	 9	 48	 	 	 	 	
	 	 	 	 LoS	 ITT	 median	
(days)	
	 	 	 	 23	 	 24	 	
	 	 	 	 	 PP	 median	
(days)	
	 	 	 	 22	 	 23	 	
	 	 	 	 Death,	30	days	 ITT	 actual	
numbers	
























T	 EII	 	 PP	 actual	
numbers	
1	 43	 2	 48	 	 	 	 	
Yang	2017	 P/T	 T	 EII	 no	relevant	outcomes	 	 	 	 	 	 	 	 	 	 	
Zhao	2017	 M	 T	 CI	 Clinical	success	(1)aa	 ITT	 actual	
numbers	
16	 25	 14	 25	 	 	 	 	
	 	 	 	 Superinfection	(1)	 ITT	 actual	
numbers	
1	 25	 4	 25	 	 	 	 	
	 	 	 	 ICU	length	of	stay	(2)	 ITT	 average	
(days)	
	 	 	 	 10	 	 10	 	
	 	 	 	 ICU	mortality	(2)	 ITT	 actual	
numbers	
7	 25	 8	 25	 	 	 	 	




	 	 	 	 7.6	 	 9.4	 	
	
	
	
	
	
	
	
	
Key	
		
ITT	 Intention	To	Treat	
mITT	 modified	Intention	To	Treat	
PP	 per-protocol	
CE	 Clinically	evaluable	
BE	 Bacteriologically	evaluable	
NE	 Number	of	evaluable	patients	
*	 those	included	in	PK/PD	analysis	
**	
limited	to	pts	with	evaluable	
samples	
	 	1	 stated	primary	outcome	
2	 stated	secondary	outcome	
-	 outcome	not	stated	a	priori	
?	
stated	a	priori	but	not	clear	if	1	or	
2	
	 	
	 	P/T	 Piperacillin/tazobactam	
M	 Meropenem	
	 	
	 	
	 	C/C	 Carbenicillin/cefamandole	
T/C	 Ticarcillin/clavulanate	
I/C	 Imipenem/cilistatin	
	 	
	 	
	 	EI	 Extended	infusion	
EII	 Extended	intermittent	infusion	
CI	 Continuous	infusion	
	 	T	 Time	dependent	kill	
C	 Concentration	dependent	kill	
MIC:AUC	 Ratio	dependent	kill	
	
	
	
	
	
	
	
	 226	
Notes	
	
	 	a	 resolution	or	improvement	of	clinical	and	laboratory	signs	of	infection	
b	 deduced	from	percentage	stated	
c	 clinical	cure	and	clinical	improvement	
d	 time	between	the	end	of	the	1st	treatment	and	the	beginning	of	a	2nd	for	the	same	
focus	of	infection	
e	 expressed	in	the	paper	as	survival	
f	 no	eradication:	clinical	recovery	but	pathogen	persistent	
g	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
h	 stated	in	method	but	then	not	reported	on	as	CI	vs	II	
i	 I've	not	included	the	pts	on	CVVH	as	they	all	received	CI	
j	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
k	 success	=	eradication/presumed	eradication,	failure	=	persistence/presumed	
persistence	
l	 limited	to	treatment-related	rather	than	all	
m	 "cure"	and	"improvement"	classified	as	successful	clinical	response	
n	 primary	outcomes	not	reported	in	the	body	of	the	paper	
o	 sample	those	patient	that	grew	a	microorganism	
p	 "resolution"	and	"improvement"		regard	as	clinical	response	for	the	purpose	of	this	
MA	
q	 success	=	eradication/presumed	eradication,	failure	=	everything	else	
r	 clinical	outcome	cure	in	the	table	and	resolution/improvement/failure	in	definition	
s	 "cure",	"improvement"	or	no	requirement	for	antibiotic	treatment	within	48hrs	of	
discontinuation	classified	as	successful	clinical	response	
t	 efficacy	defined	as	clinical	failure	(death	or	clinically	unchanged/worsening)		
u	 reported	in	both	McNabb	2001	and	Nicolau	2001	
v	 in	ICU	mortality	
w	 numbers	in	table	don't	add	up	
x	 "cure"	and	"improvement"	classified	as	successful	clinical	response	and	no	additional	
antibiotic	therapy	required	
y	 composite	of	4	elements	inc.	clinical	failure	
z	 clinical	failure	reversed	to	give	clinical	response	
aa	 clinical	success	defined	as	complete	or	partial	resolution	
	
